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The Irish Medicines Board’s 
role is to protect and enhance 
public and animal health 
through the regulation  
of medicines, medical devices 
and healthcare products.
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2 Irish Medicines Board
in 2008. We continue to co-operate closely and effectively 
with enforcement agencies throughout the EU and 
internationally and, at home, with the Garda Síochána 
and Revenue’s Customs Service. During the year, IMB staff 
identified 1,009 websites seeking to supply medicinal 
products illegally into Ireland. All were reported to the 
appropriate authority, LegitScript, the US organisation 
that facilitates the closing of rogue websites. 
We also signed an agreement with the Revenue’s 
Customs Service which improved joint Customs and IMB 
information exchange practices and procedures in relation 
to the illicit movement of prohibited and counterfeit 
products through our borders and specifically at our ports, 
airports and international postal depots. In addition, the 
IMB and Revenue’s Customs Service agreed to establish 
and operate a Joint Task Force to deal with intelligence–
driven operations and to develop training and liaison 
exchange programmes for relevant personnel.
Our work in the area of licensing medicines and medical 
devices involved us in the assessment of around  
18,000 applications relating to marketing authorisations 
for new medicines or changes to existing medicines.  
A total of 1,925 new human medicine applications were 
licensed, as well as 113 new veterinary medicines. There 
were 589 new medical devices also registered during the 
year, a twofold increase on 2008. We continue to work 
The H1N1 influenza vaccination programme was a 
significant focus for the IMB in the latter half of the year. 
The organisation was actively involved with its national 
partners, including the HSE, the Department of Health 
and Children and its working groups and with the relevant 
marketing authorisation holders, in the implementation 
of appropriate risk minimisation measures in relation to 
the programme. Following approval of the vaccines the 
IMB focussed on the safety monitoring of the vaccines 
in use. We implemented an upgrade of our website to 
support access and distribution of information relating to 
the pandemic medication. The IMB website also facilitated 
the reporting of adverse reactions particular to the 
pandemic medication by patients, carers and healthcare 
professionals. Over 900 reports of adverse reaction to 
the H1N1 vaccine were received up to the end of 2009. 
These reports contributed to an overall increase of 19% in 
the total number of adverse reaction reports received by 
the IMB during the year, up from 2,742 in 2008 to 3,276. 
Each was assessed and followed up, as appropriate, by our 
pharmacovigilance experts. 
In 2009, the number of enforcement cases initiated  
by the IMB grew from 3,037 to 3,729. The vast  
majority of these breaches related as is to mail order 
importations of prescription-only products. While this 
year’s figure represents an increase of 19% on 2008,  
it is significantly less than the twofold increase we saw  
chairman’s Statement
2009 was a significant year for the Irish Medicine’s Board (IMB), marked by a substantial increase in activity across all 
departments and an extensive involvement in the cross-agency response to the H1N1 virus. This report records the IMB’s 
progress and achievements throughout the year which testify to our dedication to the fundamental principle of the  
IMB’s existence, namely to safeguard public and animal health through the effective regulation of healthcare products. 
I would like to acknowledge and thank from the outset the management and staff of the IMB for their steadfast 
commitment to the highest standards of quality in all areas of what proved to be a demanding programme of work. 
mr. Pat o’mahony Chairman
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We thank the Minister for Health and Children and the 
Minister for Agriculture, Fisheries and Food and their 
staff. Their continued co-operation and support has 
contributed significantly to the IMB’s effective operation. 
2009 presented new challenges and placed increased 
demands on the organisation and its staff. We emerged 
with our position strengthened as a high-quality, efficient, 
service-based organisation and look forward to the year 
ahead dedicated to the safeguarding of public and animal 
health.
 
 
Pat o’mahony 
Chairman
closely with the European Medicines Agency  
(EMA) and its various working groups, and are a full  
and active participant in their licensing procedures.  
The IMB also participates in a range of other European 
and international groups, ensuring that we have access to 
the latest available information relating to the products 
we monitor and license in this country.
All of this work has been facilitated by the commitment 
and support of many. I would like to thank our Board 
members, our management and staff whose commitment 
to the IMB’s remit is reflected in the significant increase  
in deliveries across all our areas of operation this year.  
I would also like to acknowledge the independent experts 
who gave of their time and expertise throughout the 
year. Through their active contribution to our many 
committees, the IMB has access to their considerable 
expertise and insights across a wide range of disciplines. 
 Over 900 reports of adverse reaction to the 
H1N1 vaccine were received. These reports 
contributed to an overall increase of 19% 
in the total number of adverse reaction reports.
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imb board members
The Board members are:
1  Mr. Pat O’Mahony (Chairman) 
Business and Banking Consultant
2  Prof. Brendan Buckley 
Clinical Professor  
of Pharmacology,  
University College Cork
3  Mr. Pat Brangan 
Senior Veterinary Inspector, 
Department of Agriculture, 
Fisheries and Food
4  Mr. Wilfred Higgins 
Principal Engineering Advisor, 
Health Service Executive 
5  Ms. Ingrid Hook 
Senior Lecturer, School of 
Pharmacy and Pharmaceutical 
Sciences, Trinity College
6  Mr. Brendan McLaughlin 
Farmer and Elected Board Director 
in the Management Committee 
of ICSA
7  Ms. Cicely Roche 
Senior Lecturer TCD and 
Consultant Pharmacist
8  Ms. Maureen Windle 
Practitioner in Public Sector 
Healthcare Management
The Board of the IMB was appointed on 
31 December 2005 by the Minister for 
Health and Children, Ms. Mary Harney in 
accordance with the powers conferred on 
her by subsection 2 of section 7 of the Irish 
Medicines Board Act, 1995 for the period 
ending 31st December 2010.
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chief executive’s report
As we strove to continuously improve efficiencies and 
standards across the organisation, the implementation 
and management of change continued to be a key 
driver within the IMB. In March, we combined all human 
medicines, medical devices and all regulated human 
products into a new revised departmental structure.  
As a result, one department is focused on post-marketing 
safety issues for all human products, while a second is 
focused on licensing and registration activities for all 
human products. This was a major initiative and ensures 
we can deal with the full range of products, including  
new innovative and combination products. 
In early 2009, we created a stand-alone Human Resources 
department with the Director a member of the senior 
management team. This reflects our view of the central 
role that cutting-edge HR practices play in running an 
efficient and effective regulatory agency. Indeed, during 
the year we had to accommodate a moratorium on 
staffing imposed for a period by government policy 
and ensure that across-the-board salary reductions did 
not lead to any reductions in outputs or quality. I am 
grateful to all staff for their superb performance in these 
circumstances. 
We also continued to develop our quality management 
system and had all our operations assessed by a team 
of three experienced assessors from other Member 
State authorities under the Benchmarking of European 
Medicines Agencies (BEMA) programme. The outcome 
was very positive and our systems are seen as mature and 
robust. This programme is expected to continue right 
across the European Union countries and we anticipate the 
next assessment in 2012. IMB colleagues currently provide 
logistical and technical support to this BEMA programme 
and I am the co-chair of the steering committee. 
We continued in 2009 to successfully manage the affairs 
of the IMB in line with our statutory obligation that 
income at least meets costs.
We are aware of the place Ireland holds as an important 
global location for the pharmaceutical/biopharmaceutical 
and medical devices industries, and that products 
manufactured in Ireland are exported worldwide.  
The successful delivery of the IMB’s regulatory role in these 
sectors contributes greatly to this ongoing success and  
to ensuring that appropriate standards are maintained  
to the benefit of patients and consumers, both at home 
and abroad. 
HuMAN PRODuCTS MONITORING 
The Human Products Monitoring department was 
established in March 2009. This new department has a 
dedicated focus on post-marketing safety issues. 2009 
was a busy and productive year for the new department. 
The Pharmacovigilance, Medical Device Vigilance and 
Safety Assessment teams all had high levels of activity  
in managing public health issues. 
During 2009, the IMB received a total of 3,276 suspected 
adverse reaction reports to medicines in Ireland. 
I am pleased to report that 2009 was another successful year for the Irish Medicines Board with sustained achievement in 
meeting the organisation’s mission to protect and enhance public and animal health through the regulation of medicines, 
medical devices and healthcare products. Any public health issues within our remit which emerged during the year were 
handled efficiently and successfully with the protection of public health at the core of all our activities. 
mr. Pat o’mahony Chief Executive
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The online reporting system was increasingly 
used during 2009, with just over 600 reports 
submitted via this method.
The online reporting system, available to healthcare 
professionals and patients/consumers, was increasingly 
used during 2009, with just over 600 reports submitted 
by year-end via this method.
Number of adverse reaction reports 2006-2009
The outbreak of the pandemic  (H1N1) 2009 influenza 
virus in April and the implementation of the vaccination 
programme resulted in the submission of an additional 
900 national adverse reaction reports. The data from 
these reports were particularly helpful in confirming the 
expected safety profiles of these new vaccines, and the 
active participation of healthcare professionals and the 
public in notifying their experience was extremely useful 
to the monitoring process. 
A significant number of variations to product 
approvals were initiated, assessed and issued by the 
Pharmacovigilance section during 2009. These followed 
identification of specific safety issues from adverse 
reaction reports, review of cumulative safety data,  
the literature and other sources which were discussed  
and evaluated at either national or European level.  
We continued to be actively engaged in the work of the 
EMA CHMP Pharmacovigilance Working Party (PhVWP) 
and to increase the transparency of the PhVWP activities 
publication of summary PhVWP Monthly Reports after 
each meeting commenced in September 2009. 
A total of 1,335 vigilance reports for medical devices 
were received and assessed in 2009, which represented 
an increase of 15% on the number of reports received in 
2008. Class IIa and IIb general medical devices represented 
the largest number of reports received at 50%. 
During 2009, the IMB received 1,033 field safety corrective 
action notifications relating to medical devices.
HuMAN PRODuCTS AuTHORISATION AND 
REGISTRATION 
The total number of applications received from marketing 
authorisation holders in 2009 increased by 11.3% and 
total output increased by 4.8%. Of note were the numbers 
of variation applications received which were due to the 
coming into force of a new variations regulation on  
1 January 2010. 
Total new applications 2006-2009
The total output figure also increased in 2009 primarily 
due to an increase in the number of determinations of 
new national applications, new applications submitted 
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During 2009, 108 applications to conduct 
clinical trials were approved by the IMB.
chief executive’s report
There were 589 new notifications to the register for 
medical devices in 2009. A total of 365 in-vitro diagnostic 
medical devices and 224 general medical devices were 
registered. The number of new organisations registered 
was 19. 
Medical Device Registration statistics 2006-2009
During 2009, 464 compliance cases for medical devices 
were opened, which represented an increase of 22% on 
the figure for 2008. Class IIa general medical devices 
represented the largest number of compliance cases with 
single use medical device representing the most common 
type of case.
COMPlIANCE
The Compliance department continued to carry out good 
manufacturing practice (GMP) inspections on the very 
substantial number of manufacturing sites operating in 
Ireland. It also contributed significantly to inspections 
of foreign sites on our own behalf or on behalf of the 
European Union. Good distribution practice inspections 
were conducted on the supply chain while tissues and 
through the centralised and decentralised procedures  
and new Parallel Import Applications (PPA).
During the year, there was an output of 16,010 variations 
to marketing authorisations for products authorised 
through the national or Mutual Recognition (MR) 
procedures. 
During 2009, 108 applications to conduct clinical trials 
were approved by the IMB. No applications were rejected. 
Regulation (EC) 1394/2007 on Advanced Therapy 
Medicinal Products (ATMPs) came into effect in 2009. 
This Regulation provides for the authorisation of gene 
therapy, stem cell therapy and tissue engineered products. 
The Regulation also resulted in the establishment of a 
new scientific committee at the EMA, the Committee  
for Advanced Therapies (CAT). 
In 2009, the IMB carried out significant preparations in 
advance of the new ‘Variations Regulation’ (Commission 
Regulation 1234/2008) coming into force on 1 January 
2010. The new Regulation applies to both the human 
and veterinary medicinal products authorised through 
the centralised and MRP/DCP routes. The aim of the 
regulation is to introduce a simpler, clearer and more 
flexible framework on variations.
Significant work took place in 2009 in order to facilitate 
the move from paper to electronic submission of 
applications. From November, the IMB commenced 
receiving electronic submissions. It is envisaged that  
all submissions will be electronic by 2012. 
During 2009, four clinical investigation applications  
for general medical devices were received along with two 
significant amendments to previously authorised clinical 
investigations. 
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A total of 3,729 cases involving breaches of 
medicinal product legislation were initiated, 
representing an almost 20% increase from 2008.
VETERINARY MEDICINES
Animal health and welfare is of critical importance to the 
Irish economy and its reputation for producing quality 
produce. The food industry is a very important sector in 
the Irish economy with exports of €7.12 billion recorded 
in 2009. The regulation of veterinary medicines plays a 
significant part in assisting the prevention and treatment 
of disease, in enhancing animal welfare and in ensuring 
the safety of foods of animal origin. 
A record number of 2042 applications for authorisation  
of veterinary medicinal products were approved by 
the IMB in 2009. We played a leading role as reference 
member state/rapporteur in the centralised, mutual 
recognition and decentralised procedures, acting as 
reference member state for 24 outgoing applications  
for decentralised or mutual recognition procedures. 
Any pharmacovigilance and public health issues relating 
to veterinary medicines arising during the year were 
handled efficiently and effectively. There were 148  
reports of suspected adverse reactions associated with  
the use of veterinary medicinal products received in  
2009. Department staff undertook the first inspections  
of veterinary pharmacovigilance procedures in companies 
during the year with two marketing authorisation holder 
facilities being inspected. An IMB representative also 
participated in a veterinary pharmacovigilance inspection 
of a marketing authorisation holder facility in the UK as 
part of the EMA’s programme of inspections for centrally-
authorised veterinary medicinal products. 
CHIEF ExECuTIVE’S OFFICE
The Chief Executive’s Office expanded its functions  
during 2009. Alongside its core work maintaining the 
quality management system for the organisation,  
cells and blood establishment sites were also inspected. 
Licensing and export certification activities relating to Irish 
sites were carried out as were good clinical practice (GCP)
and pharmacovigilance inspections.
Number of inspections completed in 2009
During 2009, a total of 3,729 cases involving breaches of 
medicinal product legislation were initiated, representing 
an almost 20% increase from 2008. A total of 494,502 
tablets or capsules were detained, an increase of 39% 
over 2008. In addition, 1,650 packs of liquids, 449 packs 
of creams and 3,582 packs of assorted products were 
detained. Market surveillance programmes, encompassing 
investigation of quality defects and recalls, and sampling 
and analysis, were operated. A total of 495 medicinal 
products were sampled for analytical testing and /or 
checks on labelling and packaging compliance.  
Ninety-nine recalls of medicinal products were requested 
and overseen by the IMB. This represents a decrease 
of 30% on 2008 figures. Ninety-one of those related 
to human medicinal products, while eight related to 
veterinary products.
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A new communications function was 
established within the Chief Executive’s Office 
in November, with the appointment of a 
Communications and Information Manager.
chief executive’s report
FINANCE AND CORPORATE AFFAIRS
As outlined in the financial statements, the IMB’s finances 
remained stable. The accounts section continued to 
successfully manage the high volumes of work while 
maintaining high standards of internal control. The 
internal financial audit function conducted reviews of 
systems and reported directly to the Audit Subcommittee 
of the Board, in compliance with good corporate 
governance requirements. A detailed review of the  
IMB’s fee structure took place during the year. 
2009 was a busy year for corporate services as the 
increases in operations and staff outlined in all the other 
departments increased the level of services provided. 
Eighteen requests were received under the Freedom of 
Information Act in 2009, compared to twenty one in 
2008. Eleven requests were fully granted, six refused and 
one withdrawn. 
2009 continued to be a busy year in the buildings area 
in relation to ongoing maintenance of the IMB offices. 
A number of significant internal buildings projects were 
undertaken to maximise space utilisation and workflow 
efficiency. 
INFORMATION TECHNOlOGY AND CHANGE 
MANAGEMENT 
The IT and Change Management Department delivers 
specialist business analysis, information technology 
and telecommunications services throughout the 
organisation. 
We have a well-established change management 
programme since 2003, with a strong focus on 
continuous improvement. In March 2009, following 
a comprehensive review project, a new organisational 
structure was implemented to support the management 
of safety and licensing activities for all human products. 
it took over management of the website content and 
updates in March, and the co-ordination of responses to 
parliamentary questions in April. A new communications 
function was established within the Office in November, 
with the appointment of a Communications and 
Information Manager. The primary role of this new 
position is the establishment, development and 
promotion of a new communications, information  
and education function and a co-ordinated, professional 
and consistent approach to communications with  
all stakeholders. 
The Office was involved in business continuity planning 
for the influenza pandemic, ensuring that plans were 
current and appropriate to the expected impact on 
operations and that guidance was issued to staff.  
While the workload of a number of departments  
increased significantly due to licensing, pharmacovigilance 
and market compliance issues relating to the supply 
of vaccines, the overall effect on operations was 
well-managed and the expected level of outputs was 
maintained.
During 2009, a substantial increase in the implementation 
of the quality system was achieved. At the end of the year, 
74% of the total expected implementation was in place, 
up from 49% at the end of 2008. 
The IMB provides advice to stakeholders as to whether 
products should be categorised as medicinal products or 
medical devices, thereby falling under the remit of IMB,  
or whether they are outside the scope of our remit.  
The IMB Classification Committee (human medicines) 
met 10 times in 2009 and considered a total of 131  
new products. 
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In 2009, the IMB website www.imb.ie received a 
substantially higher volume of visitors than any 
other year.
A project to scan legacy documentation was commenced 
in late 2009. This initiative resulted in the transfer of over 
two million pages to the IMB systems. 
HuMAN RESOuRCES
Real effective management of performance is vital to the 
running of the IMB and we have in place a robust system 
which we title the Performance Development Programme 
(PDP).  Activities in 2009 led by HR colleagues included 
a redesign of the PDP framework for roll-out and 
implementation in early 2010; support to line managers 
in probation management; and delivery of training and 
coaching supports to staff as a result of the creation of he 
new departments of Human Products Authorisation and 
Registration and Human Products Monitoring.
We made substantial progress in the area of Learning and 
Development. A comprehensive review was conducted, 
with the purpose of developing a strategy to ensure staff 
are effectively trained and developed to meet both current 
and future needs. This process was further supported 
by the appointment of a Learning and Development 
Manager at the end of 2009. The average number 
of training days per person in 2009 was just over 3, 
continuing the trend set in 2008. There was strong focus 
on Dignity and Respect training, with a total of 21 sessions 
delivered.
2009 continued to reflect a stable industrial relation 
climate within the IMB. The staff communications group 
met regularly and each meeting was attended by a HR 
representative. Health and Safety and wellness initiatives 
during 2009 included eye tests, provisional of seasonal 
flu vaccine, a walking challenge and a series of lunchtime 
learning sessions. The uptake on all initiatives was positive.
The organisational commitment to continuous 
improvement was further strengthened by the adoption 
of ‘Lean Six Sigma’ methodology, when in the second half 
of 2009, the organisation initiated its first ‘Lean’ project in 
response to the introduction of new legislation relating to 
medicinal product licensing. 
During 2009, the IMB was influential in all aspects 
of the EU Telematics Programme. In mid-2009 the 
EMA Management Board Telematics Committee was 
established and the IMB is represented on this group. 
In 2009, the IMB website www.imb.ie received a 
substantially higher volume of visitors than any other 
year. A large part of the activity can be attributed to the 
publication of H1N1 pandemic-related information on 
the website and the facility to report adverse reactions 
associated with the vaccination programme. The IMB now 
routinely publishes all safety notices via the IMB website, 
with the facility for notification to registered users via 
e-mail or SMS. 
Extranet services continue to play a large part in  
delivering services to stakeholders. The online tracking  
and application system (RIO) remains a key system for  
the pharmaceutical industry. 
Technology to assist in compliance-related activities was 
further developed in 2009. New applications to provide 
improved planning and management of inspection-
related functions were at an advanced stage by the end 
of the year. Further developments to support market 
surveillance, controlled drugs and good distribution 
practice activities are also underway. Support was also 
provided, in advance of the proposed merger, to the  
Office of Tobacco Control.
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The IMB continued to enhance its 
communication with various stakeholder 
groups with an interest in healthcare products.
chief executive’s report
The IMB attended the fourth international summit of 
heads of medicines regulatory bodies which followed  
on from our successful hosting of this summit in 2007.  
We will participate in the organising committee for the 
2010 meeting which will be hosted in the United Kingdom. 
COMMuNICATIONS
In 2009, the IMB continued to enhance its 
communication with various stakeholder groups with an 
interest in healthcare products. A number of information 
meetings were held, these meetings attracted a large 
number of attendees and positive feedback was received. 
We also prepared for our participation, for the first time,  
as an exhibitor at the BT Young Scientist exhibition.
A number of meetings with other organisations and 
individuals with particular interests in healthcare products 
were also hosted during the year. These included meetings 
with:
 • The Animal and Plant Health Association (APHA)
 • The Association of Pharmaceutical Manufacturers of 
Ireland (APMI)
 • The Irish Association of Health Stores (IAHS)
 • The Irish Health Trade Association (IHTA)
 • The Irish Medical Devices Association (IMDA)
 • The National Standards Authority of Ireland
 • The Irish Pharmaceutical Healthcare Association (IPHA)
• Pharmachemical Ireland 
• The Pharmaceutical Distributors Federation.
PuBlICATIONS 
During 2009, the IMB launched a number of valuable 
guidance documents as part of its communications 
efforts, all of which are available from our website  
(www.imb.ie).
THE EuROPEAN REGulATORY SYSTEM AND 
INTERNATIONAl AFFAIRS
In 2009, the IMB continued to participate actively in 
the European Medicines regulatory system through its 
involvement in EU committees and working parties.  
We continued to contribute at EMA level and I continued 
in the role of chairman of the Management Board of EMA. 
The IMB also continued to contribute very actively at 
the Heads of Medicines Agencies (HMA) level, providing 
part of the Permanent Secretariat to the HMA as well as 
co-chair and technical support to the process of quality 
improvement of the European network known as BEMA. 
We were also engaged in the assessment of centralised 
applications for human and veterinary medicinal 
products as rapporteur and as reference member state 
in the mutual recognition and decentralised procedures. 
The IMB continued to meet all timelines in all these 
procedures in 2009. 
This was another active year in the European medical 
devices regulatory system with the IMB participating  
in a large number of meetings at EU level, including the 
Medical Devices Expert Group and the Classification and 
Borderline Working Group.
The IMB also continued to represent Ireland at the 
European Pharmacopoeia, where Dr. Mike Morris, Senior 
Scientific Advisor, continued to contribute at the highest 
level. During 2009, Dr. Morris delivered on a range of 
significant technical projects for the IMB.
Information technology continues to be an important 
topic on the EU agenda as it works to facilitate better 
access for patients to information on medicines  
and swift, accurate and efficient sharing of relevant 
information between regulatory authorities throughout 
Europe. During 2009, the IMB’s Information  
Technology department was actively involved in EU  
IT implementation activities.
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development opportunities so that we can maintain  
and enhance the skills set required for the ever-changing 
and increasingly complex areas under our remit. 
We will continue to review our funding provision and to 
look critically at our own cost base to ensure maximum 
use of resources. 
BOARD AND STAFF MATTERS
In total, over 100 people contribute voluntarily to the 
work of the IMB through participation on the Board and 
various Committees. The Board and Committees had a 
very successful year in office and the access we have to 
this range of independent expertise and acumen is of 
immense value to the workings of our organisation.  
I thank each member for their individual contribution  
and commitment during 2009. 
I acknowledge the support of the Ministers and staff of 
the Departments of Health and Children, and Agriculture, 
Fisheries and Food for the work of the IMB.
I welcome all new staff members who joined during 2009 
and express my personal appreciation to all the staff of the 
IMB for their continued generous support in achieving the 
Board’s objectives during the year. I look forward to the 
support of all staff in dealing effectively with the various 
challenges ahead as we continue to strive for excellence in 
all aspects of our daily activities.
 
Pat o’mahony 
Chief Executive
We will continue to offer training and 
development opportunities so that we can 
maintain and enhance the skills set required.
A number of editions of the IMB’s Medicinal Products 
Newsletter, Medical Devices Newsletter and Drug Safety 
Newsletter were published and are available on this 
website.
THE FuTuRE 
The IMB faces new challenges and new opportunities 
for development in 2010 and beyond. The economic 
downturn is a challenge for all sectors and organisations. 
Strict controls on public sector recruitment will pose 
substantial challenges to ensuring we can deliver on our 
public health remit and services to industry. 
The overall workload for the organisation continues to 
increase and diversify. Meeting this demand in the most 
efficient and effective manner will require that we carefully 
scrutinise all aspects of our organisation to ensure 
we are working in the most optimal way. A risk-based 
approach will be applied and we will actively participate 
in various work-sharing initiatives at the European 
level. Our objective will be to maintain the impetus for 
change across the organisation and continue to manage 
change to assist us in delivering ever higher standards of 
output and outcomes to all stakeholders. In this regard, 
continuing to develop our performance management, 
quality management and IT systems will be a priority. 
We are aware of the European Commission report from 
Ernst and Young on the operation of the European 
medicines regulatory system and also of proposals for 
revision of the European fees regulations. These matters 
will be considered as we prepare our next strategic plan, 
which will coincide with the next EMA and HMA strategy 
papers. A new IT strategy will also be developed in 2010.
Our staff’s expertise and experience are key assets to 
our organisation. We will continue to offer training and 
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The online reporting system available to healthcare 
professionals and patients/consumers was increasingly 
used during 2009, with just over 600 reports submitted by 
year-end via this method. Access to the online reporting 
system is through the IMB website at www.imb.ie. 
A primary objective of the IMB pharmacovigilance system 
is to provide information on new and emerging safety 
issues related to medicines in a timely fashion, aided by 
its website which includes e-mail alerting facilities. Users 
of the IMB website have the option of registering their 
contact information with the IMB to enable them to 
receive direct and immediate notification of safety and 
regulatory alerts and updates by e-mail or text message. 
To facilitate prompt access to these updates, users are 
encouraged to avail of this option by registering at  
www.imb.ie.
The IMB continued to encourage adverse reaction 
reporting and provided regular reminders about reporting 
in the Drug Safety Newsletter and its regular publications 
in MIMS (Ireland) and the Irish Medicines Formulary 
(IMF). A number of presentations on pharmacovigilance 
and adverse reaction reporting were made to healthcare 
professionals as part of under/post-graduate training, 
as well as continuing education programmes. While 
pharmacovigilance uses many sources of data, the 
need for detailed and comprehensive spontaneous 
reports remains pivotal for signal detection. The IMB is 
committed to using these data to promote the safe use 
PHARMACOVIGIlANCE 
During 2009, the IMB received a total of 3,276 suspected 
adverse reaction reports occurring in Ireland from 
healthcare professionals, pharmaceutical companies and 
patients. The IMB greatly appreciates the contribution 
of busy healthcare professionals in reporting suspected 
adverse reactions, facilitating the continued surveillance 
of the safety of medicines and, in particular, the prompt 
reporting of experience with use of the pandemic vaccines 
during 2009. While the time-consuming nature of 
form-filling and the provision of follow-up information 
to the IMB is recognised, the collection and evaluation 
of comprehensive reports are essential to ensure that 
appropriately detailed case information is available for 
the continuous surveillance of the safety of medicines 
on the Irish market. Such reports allow the IMB to make 
proposals and take regulatory action on the basis of all 
available data, including information obtained from 
spontaneous reporting. 
Number of adverse reaction reports 2006–2009
human Products  
monitoring
The Human Products Monitoring department was established in March 2009. This new department has a dedicated focus 
on safety issues relating to medicines and medical devices. Monitoring the safety of these healthcare products in the 
marketplace is the key day-to-day activity of the staff of the department. 2009 was a busy and productive year, with the 
pharmacovigilance, medical device vigilance and safety assessment teams all having high levels of activity in managing 
public health issues. 
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During 2009, the IMB received a total of 
3,276 suspected adverse reaction reports 
occurring in Ireland.
appropriate risk minimisation measures, to promote 
prompt reporting of suspected adverse reactions and 
adverse events of special interest, and to ensure active 
surveillance of medicines effective against pandemic 
(H1N1) influenza. In addition, the IMB contributed to 
monitoring and surveillance activities at EU level. 
This enhanced surveillance, together with the extent of 
exposure to the vaccines, resulted in the submission of 
an unprecedented number of national adverse reaction 
reports, with over 900 cases received up to the end of 
2009. These data were particularly helpful in confirming 
the expected safety profiles of these new vaccines and 
the active participation of healthcare professionals and 
the public in notifying their experience was extremely 
useful to the monitoring process. The commitment and 
dedication of the pharmacovigilance team who worked 
tirelessly to review and process cases and ensure real-time 
evaluation, with prompt provision to external partners, 
also contributed greatly to the process. So too did the 
internal IMB arrangement for the allocation of a staff 
member from the Human Products Authorisation and 
Registration department to provide dedicated, additional 
support. The IMB also actively participated in the relevant 
EU & WHO initiatives.
DRuGS WITHDRAWN/SuSPENDED FOR SAFETY 
REASONS
Raptiva (efalizumab)
The IMB suspended the marketing and use of Raptiva in 
Ireland on 19 February 2009 following a recommendation 
from the EMA on the same date. This national action 
was taken following review of the product by the EMA’s 
CHMP. It concluded that the benefits of Raptiva no longer 
outweighed its risks and that the marketing authorisation 
of medicines, manage risk judiciously and communicate 
safety information in a timely manner. 
Breakdown of Reports by Source
Marketing authorisation holders 1,495 
General practitioners 452 
Community nurses 328
Community care doctors 281
Hospital doctors 155
Hospital nurses 150
Hospital pharmacists 134
Patient/consumers 108
Community pharmacists 81
Clinical trials  52 
Healthcare professionals (other) 40
total 3,276
Individual case reports were followed up by the IMB, 
with feedback information provided to reporters, as 
appropriate. Relevant reports (i.e. serious, suspected 
cases) notified directly to the IMB by healthcare 
professionals were forwarded to the appropriate 
marketing authorisation holders (MAHs) and the EMA 
within the agreed timeframes and formats. The IMB also 
continued to provide details of reports received to the 
World Health Organization (WHO) for inclusion on their 
international database.
PANDEMIC MONITORING ExPERIENCE 
The IMB engaged in active and close co-operation 
with national partners, including the HSE and relevant 
marketing authorisation holders, to implement 
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A total of 2,409 periodic safety update 
reports (PSuRs) were processed during 2009.
human Products monitoring
– Sexual dysfunction 
– Depression
– Exceptional cases of interstitial lung disease, 
especially with long term therapy
• Phenytoin-induced Steven-Johnson Syndrome in 
subjects of Thai/Chinese ethnicity and association with 
HLA-B*1502 
• Short-acting beta agonists: possible risk of myocardial 
ischaemia.
PERIODIC SAFETY uPDATE REPORTS
A total of 2,409 periodic safety update reports (PSURs) 
were processed during 2009. This included reports on 
products authorised through the national, mutual-
recognition, decentralised and centralised procedures. 
The IMB continued to contribute to the EU PSUR 
Worksharing project, which aims to support increased 
performance for PSURs and to ensure a comprehensive 
and consistent safety evaluation of the active substances 
under the scheme. The IMB also continued to participate 
in the Joint PhVWP/CMDh/HMA PSUR Worksharing 
Working Group. 
Number of periodic safety update reports processed 
2006–2009
should be suspended across the EU. This followed reports 
of serious adverse reactions, including three confirmed 
cases of progressive multifocal leukoencephalopathy in 
patients who had taken Raptiva for more than three years. 
Information regarding the suspension and use of Raptiva 
in Ireland was distributed by letter/fax/e-mail networks 
to healthcare professionals. The information was also 
highlighted on the IMB and professional body websites, 
advising of the action taken and requesting that no further 
prescriptions be written or dispensed.
SAFETY VARIATIONS 
A significant number of variations were initiated, assessed 
and issued by the pharmacovigilance section during 2009. 
These followed identification of specific safety issues from 
adverse reaction reports, review of cumulative safety data, 
the literature and other sources, which were discussed  
and evaluated at either national or European level.  
During 2009, these included variations related to the 
following products.
• Non-selective alpha-blockers and phosphodiesterase- 
5-inhibitors: hypotensive effects 
• Systemic corticosteroids: risk of early psychiatric side 
effects 
• Antipsychotics: risk of venous thromboembolism 
(VTE) 
• Antipsychotics conventional (typical): small increased 
risk of mortality in elderly people with dementia 
• HMG-CoA reductase inhibitors (statins): addition of 
warnings related to:
– Sleep disturbances, including insomnia and 
nightmares 
– Memory loss
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By the end of 2009, 190 companies were in 
production with electronic reporting to the IMB.
electronic reporting were included in the quarterly IMB 
newsletter for industry.
IMB staff participated at EudraVigilance meetings 
and training courses organised by the EMA and DIA 
throughout the year.
A new adverse reactions database is currently being 
implemented to facilitate enhanced pharmacovigilance 
activities, with significant additional functionalities to 
support safety monitoring and data management activities.
INTERNATIONAl COllABORATION
CHMP Pharmacovigilance Working Party 
There were a total of 11 meetings of the CHMP’s 
Pharmacovigilance Working Party (PhVWP) during 2009. 
During these meetings, the PhVWP evaluated potential 
signals and ongoing safety concerns. It also provided 
advice to the CHMP and Member States on confirmation 
and quantification of risk and on regulatory options, as 
well as on risk management and monitoring of the impact 
of regulatory action. In addition, the PhVWP worked on 
setting standards for procedures and methodologies to 
promote good vigilance practice, communication and 
exchange of information and international co-operation. 
In order to increase the transparency of the PhVWP 
activities, publication of summary PhVWP monthly 
reports after each meeting commenced as of September 
2009. This initiative was agreed with the HMA. 
The PhVWP continued its regular interaction with the U.S. 
FDA through tele/videoconferences held during PhVWP 
meetings. 
Information was provided by the IMB pharmacovigilance 
section in respect of all requests circulated via the rapid 
COMPANY lIAISON
Advice on IMB pharmacovigilance reporting requirements 
was provided to MAHs on request throughout the year. 
Anonymised cumulative adverse reaction data were 
provided to them in respect of their products on request 
and in the case of individual serious suspected adverse 
reactions associated with use of their products, on an 
expedited basis. 
Company/sponsor compliance with pharmacovigilance 
obligations was monitored on an ongoing basis.  
This was achieved through review and monitoring of 
the timeliness and quality of individual adverse reaction 
reports, evaluation of the follow-up information provided 
for individual reports, assessment of the quality and 
comprehensiveness of PSURs/ASRs (annual safety reports) 
and responses to IMB requests for pharmacovigilance 
data. The pharmacovigilance inspection programme 
continued in 2009, involving collaboration between  
IMB pharmacovigilance and compliance colleagues.
ElECTRONIC REPORTING
The IMB continued to report all suspected serious 
adverse reactions occurring in Ireland electronically via 
EudraVigilance to the EMA and to those companies with 
whom satisfactory testing has been completed. By the 
end of 2009, 190 companies were in production with 
electronic reporting to the IMB.
Detailed information and guidance on electronic 
reporting is available from the IMB’s ‘Guide to Electronic 
Submission of ICSRs and SUSARs Associated with Use 
of Human Medicines’, which can be located under the 
heading ‘Publications’ on the website. Feedback was also 
provided to participating companies on an ongoing basis, 
and updates and items of current interest in relation to 
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As part of its strategy to strengthen  
and rationalise Eu pharmacovigilance,  
the European Commission has prepared revised 
proposals to amend the existing legislation.
human Products monitoring
WHO
IMB staff participated at the annual meeting of national 
centres participating in the WHO international drug 
monitoring programme in November 2009. Professor 
Ralph Edwards retired from his post as director of the 
Uppsala Monitoring Centre in September 2009 after 
19 years in the post. During this time, he initiated and 
implemented extensive change in the methodology for 
signalling and evaluation of adverse reaction data. He also 
contributed to many significant international initiatives 
in the development of pharmacovigilance guidance 
and standards, while always striving to enhance global 
patient safety and promote effective pharmacovigilance 
communication.
Dr. Marie Lindquist, who has worked for the organisation 
since 1979, was appointed as the new UMC director in 
2009, having previously held the post of deputy director 
and general manager. Dr. Lindquist has a distinguished 
career in pharmacovigilance and patient safety, and has 
played a central role in developing the functionality of 
the UMC activities and contributing to its reputation. 
The IMB welcomes this appointment and looks forward 
to its ongoing co-operation with her in the coming years 
and the continuing development of the UMC under 
her leadership in its important global role as the WHO 
Collaborating Centre for International Drug Monitoring.
PuBlICATIONS
As part of its commitment to ensuring access to 
information to support safe use of medicines, the IMB also 
issued a range of publications to communicate important 
safety information to stakeholders. 
Six issues of the IMB’s Drug Safety Newsletter were 
distributed to doctors, dentists and pharmacists during 
alert/non-urgent information exchange system by other 
Member States. 
The EMA engaged in close co-operation with European 
and international partners, in ensuring the availability 
and surveillance of medicines effective against pandemic 
(H1N1) influenza during 2009 and the PhVWP supported 
the activities undertaken by the EMA in this respect.  
In particular, the PhVWP contributed to the EMA’s newly 
established Pandemic Pharmacovigilance Rapid Response 
Group which provided advice on emerging safety concerns 
with H1N1 influenza vaccines and antiviral medicines.  
The IMB actively contributed to these activities and 
updates on experience with monitoring were made 
available via the EMA’s website www.ema.europa.eu.
European Commission
As part of its strategy to strengthen and rationalise 
EU pharmacovigilance, the European Commission 
has prepared revised proposals to amend the existing 
legislation (‘Regulation (EC) No 726/2004 laying 
down Community procedures for the authorisation 
and supervision of medicinal products for human and 
veterinary use and establishing a European Medicines 
Agency’ and ‘Directive 2001/83/EC on the Community 
code relating to medicinal products for human use’).
Since April 2009, the IMB has participated at monthly 
meetings of the Working Party on Pharmaceuticals and 
Medical Devices in Brussels, together with representatives 
of the Department of Health and Children. The first 
reading of the new legislation by the EU Parliament 
is expected in early 2010 and it is anticipated that the 
ordinary legislative procedure will take approximately  
two years.
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The IMB published weekly updates on the safety 
monitoring experience with the H1N1 vaccines 
nationally on its website.
information on gastrointestinal, ocular and skin 
disorders
July 2009 (32nd edition)
• Carbapenems: interaction with sodium valproate 
Bisphosphonates: risk of stress fractures;
• Mycophenolate mofetil: pure red cell aplasia;
• Exenatide (Byetta): risk of pancreatitis and warnings 
regarding use in renal impairment;
• Amphotericin: recommendations for safe prescription, 
dispensing and administration;
• Non-selective alpha-blockers and phosphodiesterase-
5-inhibitors: additional hypotensive effects following 
co-administration
Sept 2009 (33rd edition) (Special edition)
• Oseltamivir (Tamiflu) and zanamivir (Relenza)  
for pandemic H1N1 (2009)
oct 2009 (34th edition) (Special edition)
• Pandemic H1N1 Vaccines
The following publications are accessible via the  
IMB website (www.imb.ie) 
• Copies of Drug Safety Newsletters
• Direct healthcare professional communications 
(DHPC) 
• Updates on safety issues/benefit/risk evaluations 
published in the IMB’s regular columns in MIMS 
(Ireland) and the Irish Medicines Formulary (IMF) 
• Warning statements and notices on safety issues or 
benefit/risk evaluations 
The IMB published weekly updates on the safety 
monitoring experience with the H1N1 vaccines nationally 
on its website from the start of the national vaccination 
programme up to the end of 2009.
2009 and published on the IMB website. A wide range 
of safety issues were communicated in the newsletter, 
as well as two special editions on antiviral medicines and 
pandemic vaccines, in the context of the H1N1 pandemic. 
An overview of the topics covered is provided below:
February 2009 (29th edition)
• Prograf and Advagraf (tacrolimus): risk of serious 
medication errors;
• Ezetimibe (Ezetrol/Inegy): update on review of studies 
on possible increased risk of cancer;
• Inhaled anticholinergics: review of publication 
concerning risk of death or stroke;
• Ibuprofen and low dose aspirin: interaction potential 
Antiepileptic medicines: risk of suicidal thoughts  
and behaviour
april 2009 (30th edition)
• NSAIDs: new data on cardiovascular risk from 
epidemiological studies;
• Tibolone: update on breast cancer risk (Liberate Trial) 
Bisphosphonates: atrial fibrillation;
• Gadolinium containing contrast agents: update on  
risk of NSF;
• Antipsychotic medicines: risk of stroke and increased 
mortality;
• Piperacillin/tazobactam: compatibility issues
July 2009 (31st edition)
• Clopidogrel and proton pump inhibitors: interaction 
potential;
• Alli (orlistat): recommendations for safe over-the-
counter use;
• ACE inhibitors and Angiotensin II receptor antagonists: 
use during pregnancy and breastfeeding;
• Aliskiren (Rasilez): recommendations for safe use;
• Erlotinib: update on experience with use and 
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A total of 1,335 vigilance reports were 
received and assessed in 2009, which 
represented an increase of 15%.
human Products monitoring
serious adverse reactions and 32 serious adverse events 
were reported. 
TISSuES AND CEllS VIGIlANCE
The IMB attended and participated at relevant vigilance 
and surveillance meetings during 2009 to facilitate 
monitoring and revised working practices necessary 
to meet the provisions of the relevant EU and national 
legislation. The joint WHO/EU project for Standards and 
Training for the Inspection of Tissue Establishments 
(EUSTITE) was concluded. As part of this project, the 
IMB participated in a vigilance and surveillance pilot with 
partner countries to test the proposed tools and guidance. 
Further vigilance developments were planned during 
2009, including a three-year project co-funded by the 
EU Public Health group on Substances of Human Origin 
Vigilance and Surveillance (SoHOV&S). The IMB will 
participate as a partner in the various working groups 
and will act as the lead partner for one work package 
organising training courses, including e-learning modules, 
on investigation and management of vigilance and 
surveillance for tissues and cells.
The European Commission continued to progress 
harmonisation initiatives to develop a common approach 
to the provision of data by Member States through a 
Working Group on Tissues and Cells Vigilance. During 
2009 the IMB attended a meeting of this group and has 
actively participated in the development of guidance for 
reporting, which incorporated use of the tools proposed 
by the EUSTITE project. Further updates to this guidance 
are expected as experience with its use develops. 
In line with the legislative requirements, the IMB 
submitted an annual report on serious adverse reactions 
and events to the European Commission during 2009. 
The IMB also communicates directly with stakeholders, 
through the provision of information in response 
to requests. In addition, it participated at various 
meetings aimed at facilitating continued co-operation 
and collaboration with healthcare professionals, the 
pharmaceutical industry and others.
HAEMOVIGIlANCE
The IMB continued its regular meetings with the National 
Haemovigilance Office (NHO) to review haemovigilance 
events reported, discuss issues of mutual concern 
and contribute to the development of guidance on 
haemovigilance reporting. The meetings also considered 
further developments to facilitate monitoring and revised 
working practices necessary to meet the provisions of the 
EU and national legislation.
The EU Commission continued to progress harmonisation 
initiatives to develop a common approach to the provision 
of data by Member States through a Working Group on 
Haemovigilance first convened during 2007. The IMB and 
NHO continued to actively participate in this group and to 
the development of current guidance on reporting.
The IMB also presented on ‘Rapid Alerts in Tissues and 
Cells – Learning From Experience’ at the annual European 
Haemovigilance Network conference held in February 
2009.
In line with the legislative requirements and following 
collaboration with the NHO, the IMB submitted an annual 
report on serious adverse reactions and events to the 
European Commission during 2009. The report reflected 
information received from January to December 2008  
and included information on 141 serious adverse 
reactions and 55 serious adverse events. This reflects an 
increase in reporting from the previous year in which 107 
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The IMB received 1,033 field safety corrective 
action notifications relating to medical devices.
from other regulatory agencies including web postings, 
and 7% were received directly from medical device users. 
Class IIa and IIb general medical devices represented the 
largest number of reports received, at 50%. 
In the class I/IIa group there was an increased trend in 
reports relating to technical aids for the disabled, reusable 
instruments and hospital hardware. In the class IIb/III 
group, a significant number of reports were received 
relating to defibrillators (internal and external).  
An increase in the number of reports relating to diagnostic 
and radiotherapy software/equipment, ventilators and 
orthopaedic implants was also observed. 
Similar to 2008, there continued to be a large number of 
general medical device recalls relating to device packaging 
sterility and software issues particularly with diagnostic 
and treatment planning software. Single use, electro-
mechanical medical devices, non-active implantable, 
diagnostic and therapeutic radiation devices represented 
the most common reports received per product family.
In the IVD area, the largest number of reports related  
to clinical biochemistry and microbiology devices.  
As in 2008, vigilance cases relating to pregnancy tests and 
blood glucose meters accounted for a large number of IVD 
clinical biochemistry cases. Software upgrades for clinical 
chemistry analysers continued to have a high impact on 
the number of IVD clinical biochemistry vigilance cases.
During 2009, the IMB received 1,033 field safety corrective 
action notifications relating to medical devices. Of these, 
536 actions had a direct impact on the Irish market,  
38% related to field safety notices, 41% to product 
removals, 10% to software upgrades and 11% related  
to field modifications. The implementation of corrective 
actions was closely monitored by the Human Products 
Monitoring department.
The report reflected information received from January 
to December 2008 and consisted of 27 reports associated 
with use of tissues and cells, 25 of which met the 
legislative reporting requirements, including five serious 
adverse reactions and 20 serious adverse events. The 
remaining two donor reaction reports, while not fulfilling 
the mandatory reporting requirements, were included 
on a voluntary basis as requested by the Commission. 
The number of reports received in 2009 has continued to 
increase over previous years and this data will be reflected 
in the report submitted to the Commission in 2010. 
Information on reporting requirements, including a  
‘Guide to Reporting Serious Adverse Reactions (SARs)  
and Serious Adverse Events (SAEs) associated with 
Human Tissues’ and downloadable/online versions of the 
report forms are available on the IMB’s website. 
MEDICAl DEVICE VIGIlANCE 
A total of 1,335 vigilance reports were received and 
assessed in 2009, which represented an increase of 15% 
on the number of reports received in 2008. The changes 
to the MEDDEV 2.12-1 rev 5 ‘Guideline on a medical 
devices vigilance system’ continued to have an impact 
on the number of reports received, particularly in the 
reporting of field safety corrective actions (FSCAs) where 
an increase of 17% was noted. A significant increase in the 
number of National Competent Authority reports being 
circulated by Member States was a result of the improved 
clarity in the revised guidance on the medical device 
vigilance system; a total of 470 reports were circulated by 
European Competent Authorities in 2009 with the IMB 
issuing 74 reports, an increase of 27% from 2008. 
A total of 62% of vigilance reports received were from 
manufacturers or their legal representatives, 30% were 
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464 compliance cases were opened, which 
represented an increase of 22% on the figure 
for 2008.
human Products monitoring
Family groups of in-vitro diagnostic medical devices 
implicated in vigilance reports in 2009 
Outcome of field safety corrective actions in 2009
In 2009, the IMB co-operated with other European 
Competent Authorities, the European Commission and 
medical device manufacturers on several major issues 
which needed input from a variety of stakeholders.
Number of vigilance reports received 2006–2009
Family groups of general medical devices and active 
implantable medical devices implicated in vigilance 
reports in 2009
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Throughout 2009, the IMB continued its 
regular meeting schedule to communicate on 
key medical device issues with stakeholders.
a desk review involving an assessment of the ‘user 
manual’ for the meters and of the ‘instructions for use’  
for the associated reagents (strips or electrodes), with a 
focus on issues relating to maltose interference and units 
of measurement. 
PuBlICATIONS
In 2009, guidance documents were published or updated 
for stakeholders as follows:
• Thirteen safety notices
• ‘Guidelines for Safe and Effective Management and 
Use of Point of Care Testing in Primary and Community 
Care’
• Six medical device brochures for the general public
• Guidelines for industry and healthcare users on 
vigilance systems and reporting systems 
• Guidelines in relation to legislative requirements
• Manufacturers field safety notices were published on 
the IMB website.
COMMuNICATION 
During 2009, the IMB made presentations at many 
stakeholder conferences including:
• IEQAS conference
• ETCI Vigilance and Hospital Liaison
• IMDA Regulatory Forum
• BEAI Scientific Meeting
• Informa Post-market Surveillance Conference
• AOTI Conference. 
Throughout 2009, the IMB continued its regular meeting 
schedule to communicate on key medical device issues 
with stakeholders including the Department of Health 
MEDICAl DEVICE COMPlIANCE
During 2009, 464 compliance cases were opened, which 
represented an increase of 22% on the figure for 2008. 
Class IIa general medical devices represented the largest 
number of compliance cases with single-use medical 
devices representing the most common type of case.
A total of 86% of cases were notified to the IMB by other 
Competent Authorities and related to notified body 
certificate withdrawals or issues of concern in another 
Member State. As in previous years, problems identified 
and investigated as part of compliance cases included 
labelling, missing or incorrectly attached CE marking  
and classification issues. 
A number of technical files relating to Irish-based 
manufacturers were also reviewed in 2009.
Number of medical device compliance cases opened 
2006–2009
Contributions and support were also provided to the 
European working group that is planning co-ordinated 
market surveillance activity at EU level. A trilateral post-
market surveillance operation was undertaken by the UK, 
Irish and French Competent Authorities in 2009 to review 
blood glucose meters. This co-ordinated action comprised 
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The IMB continued to actively participate in 
European meetings of the Medical Devices 
Expert Group and the related working groups.
human Products monitoring
testing, classification rules, etc). The Common Technical 
Specifications (CTS) and guidance document for vCJD 
were also finalised. It is envisaged that the CTS will be 
updated as scientific knowledge develops in this area.  
The publication date for the CTS and guidance document 
has not yet been confirmed.
Three meetings of the COEN working group were held 
during 2009. Key items discussed included:
•  the work programme of COEN for 2009
• the impact of the new approach legislation and the 
draft guidance on the use of legal tools for market 
surveillance
• the guidance notes for manufacturers of class I  
medical devices
•  the guidance note for manufacturers of custom-made 
medical devices in line with the changes agreed in 
Directive 2007/47/EC. 
Updates were also provided on specific market surveillance 
projects and specific cases of concern for Member States. 
Member States were asked to comment on a future 
perspectives document.
An inter-departmental group, co-ordinated by the 
Department of Trade and Enterprise, was established to 
consider the impact of the revision to the new approach 
directive which arose out of the Commission’s concern 
relating to inconsistencies and the level of activity 
of market surveillance in Member States. Regulation 
765/2008 comes into effect on 1 January 2010. 
Several meetings of the market surveillance forum 
were held during 2009, with the focus on each agency 
preparing their market surveillance plan for 2010 for 
communication to the European Commission. 
and Children, and the Irish Medical Device Association. 
Assistance was provided to the Department on the 
transposition of Directive 2007/47/EC into Irish law. 
EuROPEAN ACTIVITY 
During 2009, the IMB continued to actively participate in 
European meetings of the Medical Devices Expert Group 
and the related working groups. 
The IMB contributed to the Vigilance Working Group 
and to the COEN Working Group. A significant focus is 
being placed on the communication of vigilance issues 
and improved co-ordination amongst Member States in 
relation to post-market surveillance. Three meetings of 
the Medical Device Vigilance Expert Group were held in 
2009. Discussion at these meetings included:
•  the recast of the medical devices directive
•  the implementation of the vigilance enquiry form
• the implementation of MEDDEV 2.12-1 rev 5
• co-ordination between Competent Authorities
• the Eudamed database
• GHTF Study group 2 
• the NCAR exchange process. 
The IMB participated in an EU Taskforce group set up 
to investigate the possible improvements of the EU 
regulatory framework concerning vigilance. Much of the 
group’s agenda focused on the identification of proposals 
for the recast of the directives. 
Two IVD Technical Group meetings took place in 
March and September 2009. During the year a small 
ad-hoc group also met to identify the technical points 
to be addressed in the context of the revision of the 
IVD Directive (for example, in-house tests, genetic 
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The following table shows the total output over the last 
number of years:
Total output for new applications 2006–2009
The total output figure increased in 2009 primarily due to 
an increase in the number of new national applications, 
new applications submitted through the centralised and 
decentralised procedures and new PPA applications.
Variations Authorised
During the year, there was an output of 16,010 variations 
to marketing authorisations for products authorised 
through the national or MR procedures. This was a 
small increase from 2008. There were 18,076 variation 
applications received, which was an 11% increase over 
2008. This was due to the uncertainty around the impact 
of the new variations regulations and the lack of clear 
guidelines on implementation. 
During 2009, the IMB undertook a reorganisation of the 
Human Medicines Department and the Medical Devices 
Department. This resulted in the creation of two new 
departments, one of which is the new Human Products 
Authorisation and Registration Department which 
became effective in March 2009. 
Significant work took place in 2009 to facilitate the move 
from paper to electronic submission of applications to the 
IMB, which commenced in November. It is envisaged that 
all submissions will be electronic by 2012.
HuMAN MEDICINES
New Products Authorised
During 2009, the IMB output for new product applications 
was 1,925. This comprised:
• 785 new national applications, including parallel 
import (PPA) applications
• 120 new mutual recognition (MR) and 439 new 
decentralised (DCP) applications
• 345 new centralised* and 216 transfer applications. 
• 20 new homeopathic applications. 
(*Total number of centralised applications complete 
in 2009, not all may be authorised by the European 
Commission at this point). 
human Products  
authorisation and registration
The total number of applications received from marketing authorisation holders in 2009 increased by 11% and total 
output increased by almost 5%. Of note were the increased numbers of variation applications received which was due to 
the coming into force of a new variations Regulation on 1 January 2010. Significant preparation was undertaken by the 
IMB in advance of the change to the variations legislation. Of note in 2009, was a substantial increase in the number of 
applications received relating to parallel-imported products. Two public consultations were carried out, on the revision  
to the dual pack registration scheme and the proposal to develop a national rules scheme for homeopathic products.
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There was an output of 991 renewals 
to marketing authorisations for products 
authorised through the national or MR 
procedures, a 14% increase.
human Products authorisation and registration
Clinical trials approved 2006–2009
A total of 448 clinical trial amendment applications were 
approved which represents a slight increase from the 
2008 figure of 429. 
Total Application Input and Output
While there was an increase in applications received 
during 2009, the total output also exceeded previous 
years as depicted below. 
Total application input and output 2006–2009
 2006 2007 2008 2009
Total input 17,895 17,471 19,657 21,879
Total output 18,314 17,252 18,668 19,566
Total output for variations 2006–2009
Renewals Authorised
During the year there was an output of 991 renewals to 
marketing authorisations for products authorised through 
the national or MR procedures. This was a 14% increase on 
the previous year.
Total output for renewals 2006–2009
The number of renewal applications received was 1,190.
Clinical Trials Authorised
During 2009, 108 applications to conduct clinical trials 
were assessed by the IMB. No applications were rejected. 
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A total of 448 clinical trial amendment 
applications were approved which represents a 
slight increase from 2008.
agencies, the IMB has taken the decision to implement the 
general principles of the new Regulation to all marketing 
authorisations from 1 January 2010. 
The aim of Regulation (EC) 1234/2008 is to introduce 
a simpler, clearer and more flexible framework for 
variations. The main changes introduced are the 
introduction of a ‘do and tell’ system for Type IA 
notifications, the change of ‘default’ category for 
variations from Type II to Type IB, the introduction of a 
‘grouping’ system for variations by the same MA holder 
and the introduction of a ‘work-sharing’ procedure. 
The variations page of the IMB website was updated 
with all relevant information including a ‘points to note’ 
document and links to the relevant European legislation 
and guidance. An information day on the new variations 
regulation will be held in January 2010. 
Parallel Imports/Dual Pack Registration Scheme
Parallel importation is the importation from an EU 
Member State or a country within the EEA of a medicinal 
product which is already authorised on the Irish market, 
by an importer who is someone other than the importer 
appointed by the marketing authorisation holder of  
the product on the Irish market. Where a product that  
is the subject of a national marketing authorisation,  
and is marketed in another Member State, is identical 
in all respects (including identical packaging, labels and 
leaflets) to the product on the Irish market, it is termed  
a ‘dual pack’. 
A consultation process on amendments to the current 
dual pack registration (DPR) scheme was carried out 
in 2009. The key proposals in the consultation were to 
introduce an over-label on the product carton which will 
include the name of the DPR holder and the registration 
Advanced Therapies 
Regulation (EC) 1394/2007 on advanced therapy 
medicinal products (ATMPs) came into effect in 2009. 
This Regulation provides for the authorisation of gene 
therapy, stem cell therapy and tissue engineered products. 
The Regulation also resulted in the establishment of a 
new scientific committee at the EMA, the Committee 
for Advanced Therapies. The committee’s composition 
includes representatives from clinical and academic 
settings and patient organisations.
The Regulation describes three procedures to be 
undertaken by the committee in relation to ATMPs; 
a classification procedure to determine if a particular 
product meets the definition of an ATMP; a certification 
procedure for committee experts to review and 
feedback on preliminary preclinical and quality data; and 
applications for marketing authorisation of ATMPs. 
The Regulation also describes criteria for assessment 
of combined ATMP products when an ATMP has been 
incorporated into a medical device. The assessment 
undertaken by the committee will include the results  
of assessment of the device by a medical device  
notified body.
New Variations Regulation
In 2009, the IMB carried out significant preparations in 
advance of the new variations regulation (Commission 
Regulation (EC) 1234/2008) coming into force on  
1 January 2010. The new Regulation applies to both the 
human and veterinary medicinal products authorised 
through the centralised and MRP/DCP routes. The 
applicability of this Regulation will be formally extended to 
‘purely national’ marketing authorisations at a later date. 
However, in line with many other European regulatory 
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A significant amount of work was undertaken to 
ensure that the infrastructure and processes are 
in place to handle electronic-only submissions 
of applications.
human Products authorisation and registration
medicinal products without indications that are 
administered orally or externally. To date, 32 products 
have been registered under this scheme (12 in 2008  
and 20 in 2009). 
Authorisation of homeopathic medicines has been 
facilitated by the introduction of recent legislation 
(Medicinal Products (Control of Placing on the Market) 
Regulations, 2007) (S.I. 540 of 2007) which defines 
criteria for the licensing of homeopathic medicines under 
national rules as provided for under Directive 2001/83/EC, 
as amended.
The IMB launched a public consultation on the proposed 
new national rules scheme in November 2009. Under this 
scheme, homeopathic medicines with indications for mild 
self-limiting conditions can be authorised. It is intended 
that the IMB will launch this scheme in 2010. 
Together with the simplified registration scheme this  
new national rules scheme will facilitate the licensing of  
all homeopathic medicines on the Irish market. 
Electronic Submissions
In 2009, a significant amount of work was undertaken to 
ensure that the infrastructure and processes are in place  
to handle electronic-only submissions of applications.  
The IMB now accepts and strongly recommends 
electronic-only submissions, either in eCTD format, non-
eCTD (NeeS) format without paper copies or through the 
IMB’s online portal RIO. This applies to new applications, 
responses to validation queries and review of assessment 
questions, supplementary information, variations, 
renewals, periodic safety update reports, and active 
substance master files / drug master files. The transition to 
electronic submissions brings with it several advantages, 
not only the obvious reduction in printing, archiving and 
transportation costs, but also facilitates consistency in 
number granted by the IMB. This activity would be 
conducted by an authorised manufacturer. Feedback was 
received and subsequent to the review it was agreed to 
proceed with the implementation of the revised procedure 
from 1 March 2010. From that date, the outer carton 
of each DPR product placed on the Irish market will be 
required to carry an over-label containing the information 
outlined earlier. In addition, all applications submitted 
from that date will be required to comply with the updated 
procedure. A ‘catch-up’ scheme for currently registered 
DPR holders will also be implemented. 
Traditional Herbal Medicines
The IMB established the Traditional Herbal Medicinal 
Products Registration Scheme on 31 August 2007. Under 
this scheme, traditional herbal medicinal products which 
meet certain criteria regarding traditional-use, safety and 
quality and are suitable for use without the intervention 
of a doctor can apply for a certificate of traditional-use 
registration using the simplified registration procedure. 
The national legislation states that no medicinal 
product may be placed on the market without a 
marketing authorisation or a certificate of traditional-use 
registration. However it provides an exemption from 
this requirement until 30 April 2011 for traditional herbal 
medicinal products that were on the market in the State 
on the coming into force of the regulations. A transition 
period for the implementation of the registration scheme 
is currently in place. In 2009, the IMB received a very small 
number of applications. Information on the scheme is 
available on the IMB website.
Homeopathics 
Homeopathic medicines can be registered or authorised 
by the IMB. Registration is under the simplified 
registration scheme specifically for homeopathic 
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2,293 queries were dealt with by the 
customer service team, of which 2,065 
related to human medicinal products.
European Commitments
Our commitments to the European medicines and 
medical devices regulatory systems continued to be 
substantial during 2009. The IMB’s technical staff serviced 
the following committees and working parties at the EMA 
and the European Commission.
information viewed across agencies, the ability to manage 
the lifecycle of the product, and improved navigation and 
assessment of documentation.
Customer Service
In 2009, 2,293 queries were dealt with by the customer 
service team, of which 2,065 related to human medicinal 
products. A large number of queries related to variations 
to marketing authorisations, renewals to marketing 
authorisations and fees for marketing authorisations.
committee/ Working Party delegate duration/ Frequency
Committee for Human Medicinal Products  Dr. David Lyons and Dr. Patrick Salmon 4 days/month
Committee for Orphan Medicinal Products Dr. David Lyons and Dr. Patrick Salmon 2 days/month
Co-ordination Group for Mutua Recognition  Dr. Jayne Crowe  3 days/month 
and Decentralised Procedures Mr. Larry O’Dwyer 
Committee on Herbal Medicinal Products Dr. Sinead Harrington/Mr. Cathal Gallagher 4 days/2 months
Paediatric Committee Dr. Kevin Connolly and Dr. Yvonne Looney 3 days/month 
 Dr. Helene Plein (Pre-clinical subgroup)
Committee for Advanced Therapies Dr. Maura O’Donovan  2 days/month 
 and/or Dr. Niall MacAleenan
Gene Therapy Working Party Dr. Vincent Irwin 6 days/year
Pharmacogenetics Working Party Dr. Helene Plein  4 days/year
Pharmacovigilance Working Party Dr. Almath Spooner  3 days/month
Safety Working Party  Dr. Lorcan Allen  2 days/3 months
Quality Working Party  Dr. Catherine Mc Hugh  3 days/2 months
Vaccine Working Party  Dr. Tracy Keane  3 days/2 months
Scientific Advisory Working Party (SAWP) Dr. Sheila Killalea  3 days/month
Efficacy Working Party  Dr. Peter Kiely 2 days/3 months
Biological Working Party Dr. Vincent Irwin/Dr. Una Moore/ 3 days/month 
 Dr. Maeve Lally
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A total of 47 classification queries were 
received in 2009.
human Products authorisation and registration
The IMB continued its participation in the peer review 
programme established by the European Notified Body 
Operations Group. The objective of this programme is to 
ensure consistency and harmonisation in the monitoring 
of notified bodies throughout the EU. As part of this 
programme, the IMB conducted a peer review assessment 
of the Italian designating authority during 2009. 
The IMB commenced a project in 2009 to update  
NSAI’s scope of designation as a notified body to align 
the existing scope with the new guidance on designation 
scope definitions arising from the Notified Body 
Operations Group. All Member States participating  
in the group have agreed to conduct a similar review 
during 2009-2010. 
Clinical Investigations 
During 2009, four clinical investigation applications for 
general medical devices were received as well as two 
significant amendments to previously authorised clinical 
investigations. 
Three applications were approved to make non-CE 
marked devices available for use on compassionate 
grounds.
MEDICAl DEVICES 
Designation and Monitoring of Irish Notified Bodies 
The IMB designates the National Standards Authority 
of Ireland (NSAI) as a notified body for conformity 
assessment of medical devices. The IMB conducted three 
surveillance audits of the NSAI to monitor its performance 
in this regard and its compliance with the medical device 
directive, the active implantable medical device directive 
and the in-vitro diagnostic device directive. Two of these 
audits were conducted at the NSAI offices in Dublin and 
one in NSAI’s US office in New Hampshire, USA.  
One observed audit of an NSAI auditor was conducted  
in 2009 i.e. where the IMB observed a selected NSAI 
auditor conducting a site audit of a client device 
manufacturer. Human Products Authorisation and 
Registration provided support to the Compliance 
department in relation to these notified body audits.  
One additional ‘for-cause’ audit of NSAI was required late 
in 2009 due to a compliance issue that was identified with 
one of NSAI’s client manufacturers. 
See also under ‘Compliance – Inspection/Audit’ for 
statistics on audits of medical device manufacturers  
on page 39.
European Commitments (continued)
committee/ Working Party delegate duration/ Frequency
Blood Products Working Party Dr. Tracy Keane  2 days/3 months
Clinical Trials Facilitation Group Dr. Brian Aylward  2 days/3 months
MDEG Classification & Borderline Working Group Dr. Paul Scannell/Dr. Niall MacAleenan 3 days/year
MDEG Clinical Investigation & Evaluation  Dr. Niall MacAleenan  3 days/year 
Working Group
EUDAMED  Dr. Paul Scannell  3 days/year
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There were 589 new notifications to the 
register for medical devices in 2009.
Source of classification queries 2009
Registrations 
There were 589 new notifications to the register for 
medical devices in 2009. A total of 365 in-vitro diagnostic 
medical devices and 224 general medical devices were 
registered. The number of new organisations registered 
was 19. The data collected on the registration database 
were uploaded on a monthly basis throughout 2009  
to the European Commission’s EUDAMED database.  
A review of the fees and procedure for registration of 
medical devices in Ireland was commenced during the 
year, to be completed during 2010.
The IMB continues to promote communication 
with clinical investigators, manufacturers and other 
investigation sponsors on clinical investigation issues. 
This approach, including pre-submission queries 
and meetings, helps to clarify expectations and data 
requirements and facilitates the review process. During 
2009, the IMB undertook a further analysis on the legal 
aspects of adopting a parallel review approach to clinical 
investigations such that the IMB reviews applications at 
the same time as the relevant ethics committee. 
Classification Requests 
A total of 47 classification queries were received in 
2009. 51% originated from other national Competent 
Authorities, 38% from other external stakeholders 
(including 9% from NSAI) and 11% were internal 
queries. Of the 47 classifications, 7 related to drug-device 
combination or borderline products that required referral 
to the IMB’s Classification Committee.
The IMB contributed to the European system achieving 
classification consensus through the Classification and 
Borderline working group. In 2009, the IMB referred 
one borderline product to the working group for further 
discussion.
Classification files 2006–2009
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During 2009, 487 queries on medical devices 
were received from external stakeholders.
human Products authorisation and registration
Publications
• In 2009, the guidance document ‘Guide to the 
classification of a medical device’ was updated for 
stakeholders.
• Three medical device newsletters were issued during 
2009 and these continue to be well received by 
stakeholders.
• Many contributions were received towards newsletter 
articles from academia, the healthcare sector and 
industry, highlighting different medical device issues.
Communication
During the year, the IMB made presentations at several 
stakeholder conferences including the Irish Cardiovascular 
Alliance Conference on conducting clinical investigations 
involving medical devices.
Throughout the year, the IMB continued its regular 
meeting schedule to discuss key medical device issues 
with stakeholders including the Department of Health and 
Children, NSAI and the Irish Medical Devices Association.
In 2009, 487 queries on medical devices were received 
from external stakeholders, including 370 related to  
pre-market issues, 98 related to post-market issues,  
two related to audit issues and 17 miscellaneous queries. 
European Activity
During 2009, the IMB made significant contributions to 
European meetings of the Medical Devices Expert Group 
and the related working groups. Due to organisational 
commitments the IMB delegate resigned as the Chair of 
the Compliance and Enforcement Network. 
The IMB provided a medical device delegate to the newly 
created Committee for Advanced Therapies at the EMA.
Medical device registration statistics 2006–2009
ACMD
The Advisory Committee for Medical Devices (ACMD) met 
three times during 2009, with topics discussed including 
guidance on the safe and effective use of ‘point of care 
testing’, criticality of IT networks in healthcare settings, 
and monitoring of notified bodies for medical devices.  
The ACMD also endorsed a series of brochures for the 
public to promote the safe and effective use of medical 
devices. The brochures were distributed to selected 
healthcare settings and are available from the IMB on 
request or can be downloaded from the IMB website.
In collaboration with the faculty of pathology, clinical 
biochemists and medical scientists, the IMB published 
‘Guidelines for Safe and Effective Management and  
Use of Point of Care Testing (POCT) in Primary and 
Community Care’, settings including primary care centres, 
pharmacies etc. This document complements guidance on 
the use of POCT in hospital settings which was published 
during 2008. 
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The IMB made significant contributions to 
European meetings of the Medical Devices 
Expert Group and the related working groups.
The IMB also continued its active participation in the 
Clinical Investigation and Evaluation Working Group, 
the Classification and Borderline Working Group and the 
Notified Body Oversight Group.
Ireland participated in two meetings of the Presidencies  
of the EU, namely the Czech Republic and Sweden.
As outlined above, during 2009 members of the Human 
Products Authorisation and Registration department 
contributed to European meetings including the 
Medical Device Expert Group, the Clinical Investigation 
and Evaluation Working Group, the Classification and 
Borderline Working Group, the EUDAMED working 
group and the Notified Body Operations Group. The IMB 
made significant contributions to European regulatory 
documents published during 2009 including the revision 
to the MEDDEV guidance on Clinical Evaluation.
In 2009, Directive 2007/47/EC was transposed into Irish 
law by way of European Communities (Active Implantable 
Medical Devices) (Amendment) Regulations, 2009  
(S.I. 109 of 2009) and European Communities (Medical 
Devices) (Amendment) Regulations, 2009 (S.I. 110 of 
2009). The IMB provided support to the Department of 
Health and Children on the transposition of this Directive.
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(52 reports), equine (2 reports), ovine (22 reports), feline 
(8 reports), porcine (5 reports) and rabbit (1 report).
Of the 148 reports associated with the use of veterinary 
medicinal products, 73 related to suspected adverse 
reactions in the treated animals, 66 related to suspected 
lack of expected efficacy, 4 related to maximum residue 
limit violations and 5 reports involved suspected adverse 
reactions in individual users following exposure to a 
veterinary medicinal product. No regulatory action was 
taken in 2009 relating to issues of target animal or user 
safety as a result of spontaneous adverse reaction reports.
OPERATIONAl PERFORMANCE
The department reached a record output of 2,042 units. 
This figure was comfortably ahead of the target of 1,680 
set in January 2009. 
As in previous years, the department focused on three 
main areas:
Excellence in our work
37 new or updated standard operating procedures were 
approved during the year:
• six audits of various procedures operated in the 
department were undertaken by the IMB’s quality 
management section
• the introduction of a new key performance indicator 
on quality of authorisations issued
• exemplary assessments peer-reviewed by the 
IMB’s expert advisory committee as well as the 
A detailed review of operational performance, customer 
service, and organisational development is provided 
together with a report on pharmacovigilance monitoring 
for the year.
PHARMACOVIGIlANCE
Department staff participated in the first inspections of 
veterinary pharmacovigilance procedures in companies 
during the year with two marketing authorisation holder 
facilities being inspected – see also page 38 under 
‘Compliance – Inspection/Audit’. An IMB representative 
also participated in a veterinary pharmacovigilance 
inspection of a marketing authorisation holder facility  
in the UK as part of the EMA’s programme of inspections 
for centrally-authorised veterinary medicinal products  
in 2009. 
REPORT OF SuSPECTED ADVERSE REACTIONS FOR 
2009
There were 148 reports of suspected adverse reactions 
associated with the use of veterinary medicinal products 
received by the IMB in 2009. Some 126 of the reports 
originated from marketing authorisation holders, 
19 reports were received from veterinarians or other 
healthcare professionals and 3 reports were submitted by 
animal owners. In these reports, a total of 75 veterinary 
pharmaceutical products and 73 immunological products 
were identified as possibly associated with adverse events. 
Suspected adverse events were reported in the following 
species: human (5 reports), bovine (53 reports), canine 
Veterinary medicines
The year 2009 marked the second full year of operation under the new management structure in the Veterinary Medicines 
department. It was another year of record achievement. While the operating environment both internally and externally 
continued to pose financial and other challenges, the department continued to deliver expected outcomes. 
dr. J.g. beechinor  Director of Veterinary Medicines
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The department reached a record output of 
2,042 units; this figure was comfortably 
ahead of the target of 1,680.
As in previous years, personnel from the department held 
a number of meetings with stakeholders, including the 
Department of Agriculture, Fisheries and Food.
The Director of Veterinary Medicines continued to be 
active in initiatives intended to support availability of 
veterinary medicines.
 Concerning national issues on veterinary medicinal 
matters, departmental personnel also provided input into 
regulatory seminars on veterinary medicines to the Royal 
College of Surgeons.
The department continued its work-sharing, 
harmonisation and joint-labelling initiatives with the 
UK’s Veterinary Medicines Directorate. While delivering 
a practical benefit to companies and the animal health 
industry in the delivery of joint labelled veterinary 
medicines for the UK and Irish markets, such co-operation 
helps ensure that the IMB retains flexibility to manage 
varying workloads. 
ORGANISATIONAl DEVElOPMENT
The vision of the management team for the department 
is to develop “an inspired and fulfilled team delivering an 
innovative, informative and responsive regulatory system 
for veterinary medicines which enhances the lives of 
animals and safeguards the health of society.” 
The department continued to invest in the training and 
development of staff so that the IMB can continue to 
meet its performance criteria. During the year, there 
were a number of changes in personnel. The IMB wishes 
to acknowledge the contribution of colleagues who left 
the department during the year. While staff changes can 
be somewhat disruptive to the smooth running of the 
business, it is our hope and expectation that our new 
benchmarking assessment of the department’s 
assessment, authorisation and pharmacovigilance 
systems under the BEMA programme.
Efficiency
The department processed all centralised, decentralised 
and mutual recognition applications in accordance with 
the agreed timetables. The number of applications held in 
the work-in-progress queues declined from 690 units in 
December 2008 to 645 units in December 2009. 
Added-value
The department acted as reference member state for 
24 outgoing applications for decentralised or mutual 
recognition procedures. This service to industry supports 
Irish and European jobs and places the IMB amongst  
the top two Member States in Europe for such work.
CuSTOMER SERVICE
Customer service remains an important focus for the 
department, which continued to build on previous 
achievements and on meeting or exceeding its overall 
service targets, and appreciates the trust placed in it by 
stakeholders. During the year the department expanded its 
focus on the ongoing monitoring of veterinary medicines 
and strengthened the number of personnel engaged in 
pharmacovigilance. It also hosted an information day in 
September which was well-attended by stakeholders.
The IMB initiated a public consultation to seek input into 
its policy on the appropriate supply categories and criteria 
for supply for antiparasitic veterinary medicine intended 
for dogs and cats. 
The department contributed articles to all of the IMB 
newsletters during the year and published one article on 
antimicrobial resistance in the Irish Veterinary Journal.
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There were 148 reports of suspected adverse 
reactions associated with the use of veterinary 
medicinal products received by the IMB.
Veterinary medicines
colleagues quickly learn the business and will bring new 
knowledge to their roles. During 2009, there was a change 
in the Irish representation at the Committee for Medicinal 
Products for Veterinary Use (CVMP). Dr. David Murphy 
was appointed as CVMP member and Dr. J.G. Beechinor 
as alternate CVMP member. In 2009, Mr. Paul McNeill 
was appointed delegate to the Co-ordination Group 
for Mutual Recognition and Decentralised Procedures 
(CMDv). 
The Director of Veterinary Medicines continues to 
seek to improve the department’s dynamic capabilities 
through organisational learning and staff development 
opportunities. The department continues to input to EU 
strategies which are expected to further these objectives in 
the years ahead.
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in processing licences, organisation of inspections, 
quality defect and recall management.
• Provision of support to the Department of Health and 
Children in the revision of legislation to prevent the 
entry of falsified medicines into the legal supply chain.
• Monitoring via inspections of the implementation of 
updated good manufacturing practice requirements 
and pharmacovigilance inspection standards.
• Active participation in harmonising standards and 
inspection practices through EMA working groups and 
the Pharmaceutical Inspection Co-operation Scheme 
(PIC/S) Committee and Expert Circle meetings.
• Active participation in European and international 
enforcement groups aimed at countering the threat 
from illegal and counterfeit medicinal products and 
medical devices. 
INSPECTIONS AuDIT
The IMB’s Compliance inspections function is structured 
within four operational groups:
• Good Manufacturing Practice (which incorporated 
medical device auditing from March 2009) 
• Controlled Drugs and Good Distribution Practice 
• Good Clinical Practice and Pharmacovigilance 
• Blood and Tissues 
The number of licences/authorisations applied for 
and issued levelled off between 2007 and 2009. This 
could indicate a steadying of industry activity in terms 
of the export of pharmaceutical products and few 
new undertakings that would require inspection and 
authorisation. 
The number of inspections conducted at Irish-based 
pharmaceutical manufacturers decreased in 2009. 
This decrease can be attributed, in part, to improved 
scheduling of inspections of holders of multiple licences  
so that they occurred within the same site visit. 
The number of inspections carried out at foreign 
manufacturing sites was 21 which represented about  
one quarter of the inspection programme in terms of  
sites inspected.
HIGHlIGHTS OF THE DEPARTMENT’S 
ACHIEVEMENTS IN 2009
Initiatives undertaken in 2009 included:
• Full implementation of the new organisational 
structure with integration of medical device auditing 
and the cosmetics project within the Compliance 
Department.
• Thirty-six medical device audits were conducted, 
exceeding the target of 30.
• Further development of a workflow database for 
compliance case management to improve efficiency  
compliance
As part of the reorganisation of the Human Medicines and Medical Devices departments, additional functions transferred 
to the Compliance department in March 2009. These were medical device auditing, issuance of certificates of free sale for 
medical devices and the project for future integration of the Competent Authority role for cosmetics. The transfer of staff 
had minimal impact on the work output and medical device audit programme and the integration of new colleagues and 
processes continued to be one of our main focuses throughout 2009.
mr. John lynch  Director of Compliance
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128 good distribution practice (GDP) 
inspections were carried out in order to evaluate 
the level of compliance.
compliance
Inspectors completed 23 GCP inspections. Of these,  
15 were carried out at sponsor and investigator sites in 
Ireland. The other six inspections were conducted at the 
request of the EMA. 
Five pharmacovigilance inspections were performed at 
Irish-based marketing authorisation holders’ facilities. 
These included inspections of two veterinary marketing 
authorisation holders to evaluate the systems and staffing 
in place for dealing with pharmacovigilance. 
Blood Bank/Establishment and Tissue Establishment 
Inspections 
Eight blood establishment inspections and one blood 
bank inspection were conducted. 
Fifteen tissue establishments were inspected. The main 
focus of this inspection programme related to follow-up 
actions from previous inspections of holders of tissue 
establishment authorisations.
Performance Targets
time taken to close-out an inspection
The target for close-out of inspections is 90 days. In order 
for an inspection to be closed out, the inspector must be 
satisfied that the company or investigator is compliant 
and that all deficiencies identified during the inspection 
have been addressed. 
In 2009, the on-time target for close-out was achieved for 
58% of inspections performed.
Of the inspections that were closed in 2009, the average 
time for close-out was 112 days. 
Good Manufacturing Practice
A total of 88 good manufacturing practice (GMP) 
inspections were performed. These included 21 
inspections in non-EEA countries, five of which were 
carried out at the request of the EMA for centrally-
authorised products. Thirty-six medical device audits were 
conducted, 31 of which were of device companies, and five 
of which were of notified bodies.
Controlled Drugs and Good Distribution Practice 
A total of 128 good distribution practice (GDP) 
inspections were carried out in order to evaluate the level 
of compliance with the GDP requirements and to assess 
applications for new authorisations and variations to 
existing authorisations. 
The programme also included a number of inspections 
that were specifically targeted at wholesalers/distributors 
involved in the distribution of parallel imported medicinal 
products to assess the compliance of products supplied to 
the market.
Twenty controlled drugs inspections were conducted.  
The inspection programme focussed on licensed 
distributors and manufacturers of controlled drugs.
Good Clinical Practice and Pharmacovigilance 
Inspections 
The good clinical practice (GCP) inspection programme 
included inspections at sponsor companies, investigators, 
contract research organisations and laboratories and 
applied to clinical trials approved in Ireland and those 
performed in support of national or EU marketing 
authorisations.
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Inspectors completed 23 good clinical practice 
(GCP) inspections. Of these, 15 were carried 
out at sponsor and investigator sites in Ireland.
lICENSING
The total number of licences or authorisations in force 
at year-end, and in the previous two years, is presented 
below by category.
total number of licences  
/ authorisations (Sites) 2007 2008 2009
Manufacturers of Medicinal  85 86 85
Products for Human Use
Manufacturers of Veterinary  28 26 25
Medicinal Products
Manufacturers of Investigational  43 45 50
Medicinal Products
Wholesalers of Medicinal  127 214* 210*
Products for Human Use
Blood Establishments 4 6 5
Tissue Establishments 0 6 13
Laboratory Certificates 12 11 11
* Includes wholesalers supplying general sale products only
The Licensing section continued to support the Inspection 
section with regard to the issuing of GMP certificates 
within 90 days following an inspection.
controlled drugs  
licensing activity  2007 2008 2009
Registration  19 23 20
Export and Import 964 1056 998
Annual – New 19 19 31
Annual – Renewal  171 243 224
Letter of No Objection (LONO) 473 489 447
Pilgrims 14 14 11
Hemp 5 46 7
inspection statistics
Number of inspections completed in 2009
Total number of inspection days per sector 2009
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There was an output of 3,109 export 
certificates during 2009.
compliance
EudraGMP
The information in the EudraGMP Community database 
is divided into two parts. The first part comprises all 
manufacturing and importation authorisations (MIAs) 
issued by EEA Competent Authorities in their respective 
territories. The second part includes GMP information, 
in the form of GMP certificates or GMP non-compliance 
information, for all authorised sites in the EEA and for 
inspected sites in third countries. 
The EMA launched version 2.0 EudraGMP in July 2009. 
Among other improvements, EudraGMP v2.0 provides 
access to the general public for MIAs and GMP certificates, 
with the exception of any information of a commercial or 
personal confidential nature. EudraGMP can be accessed 
via the EMA website eudragmp.emea.europa.eu
In common with a number of other Member States, 
details of MIAs and GMP certificates issued by the IMB 
are not yet available via public access on the EudraGMP 
database. At year-end, the IMB was working on a project 
to reformat all MIAs into the required EU format and 
to electronically upload the necessary information to 
EudraGMP.
In addition, a new procedure on dealing with serious GMP 
non-compliance was published in the EU Compilation of 
Community Procedures.
Issuing of Free Sale Certificates for Medical Devices 
As part of the change management programme,  
the issuing of free sale certificates for medical devices 
transferred to the licensing section of the Compliance 
department on 2 June 2009. Applicants were able  
to submit all applications electronically to  
exportcerts@imb.ie.
ExPORT CERTIFICATES 
There was an output of 3,109 export certificates as set 
out below. Note that issuing of medical device certificates 
transferred to the Compliance department during 2009.
Product certification activity  2007 2008 2009
Certification of Documents 316 266 235
Certificates of Free Sale 52 22 22
Certificate of Good Manufacturing  
Practice for Finished Product  
Manufacturers 200 212 230
Certificate of Good Manufacturing  
Practice for Active Substance  
Manufacturers 62 42 39
Certificate of a Pharmaceutical  
Product for Human Use 941 1,236 853
Certificate of a Pharmaceutical  
Product for Veterinary Use 105 37 89
Medical Device Free Sale  
Certificates – – 1,585
Other 82 61 56
Total 1,758 1,876 3,109
Electronic Applications for Authorisations / Licences 
and Export Certificates 
With the objective of reducing paper usage and storage 
costs, the Compliance department began accepting 
applications via electronic mail for all licensing and export 
certificate applications. This is optional and as for any 
standard electronic mail, the security of transmission is 
not guaranteed. Electronic documentation may also be 
provided on CD or DVD. 
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analytical testing activities
A total of 286 medicinal and other products were sent 
for analytical testing, of which 278 were obtained from 
the Irish marketplace and eight originated from other EU 
markets. This represented an increase of 27% over 2008.
information on the product  no. of samples 
categories selected for sent for analysis 
analytical testing in 2009 (% of total)
Physico-chemical Analysis:
Active substances 53 (19%)
Medicinal products for human use  
manufactured for export  5 (2%)
Nationally-authorised biological  
medicinal products for human use  21 (7%)
Nationally-authorised medicinal products  47 (16%)
MRP/DCP authorised medicinal  
 products for human and veterinary use 28 (10%)
Parallel imported (PPA and DPR)  
medicinal products  9 (3%)
Centrally-authorised medicinal products  
for human and veterinary use 10 (4%)
Borderline medicinal / non-medicinal  
products for human use  14 (5%)
Enforcement-related products for human use  83 (29%)
Microbiological Analysis:
Nationally-authorised medicinal products  
for human use  9 (3%)
Medical devices for human use  
(analysed at the request of Medical Device  
colleagues within the IMB) 7 (2%)
total 286
MARkET COMPlIANCE
Overview
The Market Compliance section runs a number of  
risk-based, compliance-related programmes.  
These include: 
• Proactive market surveillance activities, such as the 
sampling and analysis programme.
• Reactive market surveillance activities, such as those  
of the quality defect and recall programme.
• Exempt medicinal products programme, which is a 
notification system relating to the importation and 
supply of unauthorised medicinal products in Ireland. 
• Regulatory compliance inspections at the premises of 
marketing authorisation holder companies, designed 
to assess the level of compliance against various items 
of national legislation pertaining to the marketing and 
advertising of medicinal products. 
• Advertising compliance programme for medicinal 
products for human use, which commenced formally 
in May 2009. 
In the following sections, a summary of the activities for 
2009 in each of the above areas is presented.
Sampling and Analysis Programme
The sampling and analysis programme is risk-based 
and includes authorised medicinal products, products 
manufactured in Ireland for export only, active substances, 
enforcement-related samples and borderline products.
During 2009, 495 products, spanning the categories 
referred to above, were sampled and were either subjected 
to analytical testing and/or packaging and labelling 
examination work.
286 medicinal and other products were sent 
for analytical testing, an increase of 27% over 
2008.
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16 non-compliances of packaging and 
labelling were identified across 15 authorised 
medicinal products.
compliance
Breakdown of the types of examinations carried out 
on authorised medicinal products
Packaging and labelling findings
Sixteen non-compliances were identified across  
15 authorised medicinal products. Eight of these related 
to the Braille on packaging, four related to the absence of 
an approved warning, and four related to non-compliant 
pack overlabels. 
In addition to the above findings, 16 unauthorised 
medicinal products were identified on the Irish 
marketplace. 
Participation in EU Co-ordinated Market Surveillance 
Activities
The IMB is an active participant in EU programmes that 
involve the sampling and analysis of medicinal products. 
This is achieved via its participation in the Official 
Medicines Control Laboratory (OMCL) Network. 
The IMB participated in the sampling and analysis of 
centrally-authorised medicinal products. Five were 
sampled from the Irish marketplace for testing at OMCLs 
in other countries, and a further five were analysed in 
Ireland on behalf of the EMA. 
Principal findings from analytical testing
Nineteen out-of-specification results were obtained 
during testing of 17 authorised medicinal products.  
One related to supra-potent assay values in three different 
batches of the same medicinal product; two related to 
an impurity above the authorised specification in two 
different medicinal products; and one related to the  
failure to comply with the registered uniformity of content 
specification. The remaining 13 related to non-compliance 
with specifications for appearance. These cases were 
investigated and appropriate action was taken.
Packaging and Labelling Examinations
A total of 209 medicinal and other products were 
examined of which approximately 12% were parallel 
imported medicinal products (PPAs or DPRs). This was an 
overall increase of 14% (approx) on 2008. The table below 
shows the general categories:
description of products  no. of samples examined 
examined (% of total)
Medicinal products subjected to  
packaging and labelling monitoring 128 (69%)
Medicinal products subjected to  
Braille-compliance checks 20 (10%)
Medicinal products associated with  
quality defects and/or recall issues 13 (8%)
Borderline medicinal/non-medicinal  
products associated with IMB Classification  
Committee work 48 (23%)
total 209
Package leaflet check 
58%
Compliance to 
packaging and labelling 
requirements 5%
Quality of the 
packaging 5%
Warning 
statements 19%
Compliance of 
overlabelling 8%
Medication error 
complaints 5%
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614 quality defects in human and veterinary 
medicinal products were reported to, or 
identified by, the Market Compliance section.
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QuAlITY DEFECT AND RECAll PROGRAMME 
The quality defect and recall programme investigates, on 
a risk-basis, reports of suspected quality defects in both 
human and veterinary medicinal products, and in their 
related active substances. A total of 614 quality defects in 
human and veterinary medicinal products were reported 
to, or identified by, the Market Compliance section. This 
represents an 11% increase over 2008 figures. Factors that 
contributed to this increase included educational work 
carried out by the section with manufacturers in relation 
to what should be reported as a quality defect, as well as 
promotion of the use of the IMB’s online reporting system. 
Of the 614 cases, 469 were determined to be affecting 
Ireland, meaning that the defective batch or batches  
were either on the Irish market and/or were manufactured 
in Ireland. 
As part of work-sharing and efforts to make the best use 
of laboratory resources, the IMB actively participated in 
the EDQM-co-ordinated surveillance programme for 
MRP/DCP medicinal products. Seventeen products from 
the Irish marketplace were analysed by other Member 
State OMCLs. Twelve borderline medicinal/non-medicinal 
products were analysed at the IMB’s request at the UK’s 
OMCL. Other work-sharing included: 16 medicinal product 
samples were microbiologically analysed at the OMCL  
of the Czech Republic for the IMB, 21 biological products 
(heparins and low-molecular weight heparins) were 
analysed for the IMB at Sweden’s OMCL, four medicinal 
product samples were analysed at one of the French 
OMCLs, and nine samples were analysed for the IMB at the 
Finnish OMCL.
classification of quality defects 2006-2009 2006 2007 2008 2009
Critical quality defects 84 173 127 105
Major quality defects  238 216 299 345
Minor quality defects  40 80 105 147
Number of quality defect reports not justified 9 4 23 17
total number quality defects reported/identified for the year  371  473  554  614
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Major and critical cases accounted for 73% 
of all reported quality defects.
compliance
may be partially due to the fact that the GMP requirement 
for batches to be placed in an ongoing stability 
programme, under ICH conditions, was first introduced in 
mid-2006, and these first batches are now further along 
in their shelf life and thus more likely to be the subject of 
out-of-specification results. 
Particulate, microbial, chemical and other product 
contamination accounted for 13% of all reports. Of the  
82 contamination cases, 15 related to the contamination 
of numerous heparin batches worldwide. These cases were 
investigated at European level and appropriate action was 
taken in Ireland.
Defects under the category ‘Other’ (16%) included non-
compliances with GMP, erroneous product distribution 
and other supply issues. 
Major and critical cases accounted for 73% of all reported 
quality defects. Of the 105 critical cases, 45 directly 
affected Ireland. This represented a 22% decrease on  
the 2008 figure and is seen as a positive development.  
Of these, 44 concerned medicinal products for human  
use and one related to a veterinary medicinal product. 
For eight of the 105 critical cases, it was not possible to 
conclusively determine whether the concerned medicinal 
products were on the Irish market. None of these products 
were authorised and all were distributed via unauthorised 
supply routes (such as the internet). 
The table below shows the areas in which quality defects 
occurred. A total of 23% concerned packaging and/or 
labelling issues, down from 38% in 2008.
Stability-related cases almost doubled and accounted for 
16% of all quality defect reports in 2009. This increase 
areas of Quality defects for 2009 human Quality Veterinary Quality human and Vet 
 defects (%) defects (%)  Quality defects (%)
Packaging and/or labelling  24  7.9  23 
Stability  16  13  16 
Non-compliance with PA/VPA  4.3  2.6  4.2 
Product safety-related  4.5  0  4.2 
Non-compliance with specification  3.6  29  5.2 
Non-adherence to cold chain requirements  0.2   0  0.2 
Microbial, chemical and particulate product contamination 13  21  13 
Product mix-up  4.2  0  3.9 
Unauthorised product  7.1  18  7.8 
Lack of therapeutic efficacy  0.4  0  0.3 
Damaged product  2.1  0  2 
Potential counterfeit  1.4  0  1.3 
Product usage  3  0  2.8 
Other  16  7.9  16 
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The recall from the Irish marketplace of a 
batch or a number of batches occurred in 
approximately 16% of all quality defect cases.
There was a significant decrease (61%) in the reporting  
of quality defects by community and hospital pharmacists 
when compared with 2008 figures. This highlights the 
need for ongoing promotional work in the area of quality 
defect reporting, and this area will a focus in 2010. 
A total of 150 quality defect and recall notifications 
were received from Competent Authorities and Official 
Medicines Control Laboratories (OMCLs) in other 
countries. Each of those reports was investigated to 
establish if the report had any potential implications for 
the Irish market, and where necessary, action was taken. 
The recall from the Irish marketplace of a batch or a 
number of batches of a medicinal product occurred in 
approximately 16% of all quality defect cases in 2009.  
This is a reduction from the 2008 figure of 26%, and this 
is seen as a very positive development – see recalls  
section below.
Recalls of Human and Veterinary Medicinal Products 
A total of 99 recalls of medicinal products were requested 
and overseen by the IMB. This represents a decrease 
of 30% on 2008 figures. Ninety-one of those related 
to human medicinal products, while eight related to 
veterinary products. The different categories are shown  
in the tables overleaf.
Unlicensed products on the Irish market accounted for a 
significant number of recalls. 54% of all reports for this 
category came directly from IMB staff, particularly from 
inspections of wholesalers. Distribution of unauthorised 
products is an ongoing concern for the IMB and three ‘for-
cause’ inspections of wholesalers were carried out  
as a result.
Sources of human medicinal product quality defect 
reports
Sources of veterinary medicinal product quality 
defect reports
In relation to the sources of human and veterinary quality 
defect reports in 2009, the graphs above present a 
breakdown of where the reports came from. The following 
points are some high level observations on the data above.
IMB Staff Members 16%
Competitor Companies 
0.4%
Physicians and Nurses 
0.5%
Other Competent 
Authorities 24%
Community Pharmacists 
19%
Hospital Pharmacists 6%
Companies 51%
Patients and/or Members 
of the Public 0.5%
IMB Staff Members 21%
Other Competent 
Authorities 37%
Department of 
Agriculture, Fisheries 
& Food 21%
Companies 
(Manufacturers, 
Distributors and/or 
VPA Holders) 21%
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A detailed review of the quality defect and recall 
programme was performed to identify further risk-
based process improvements and efficiency gains.
compliance
breakdown of human medicinal Product recalls from the irish market 2006 2007 2008 2009
Packaging and/or labelling  14  21  72  19
Stability  3  3  6  2
Non-compliance with MA  0  6  3  1
Sterility assurance and various other product safety concerns  8  13  5  9
Non-compliance with specification  4  1  9  7
Non-adherence to cold chain  0  19  1  0
Particulate or other contamination  4  12  5  6
Product mix-up  3  1  3  1
Unauthorised product  11  4  15  35
Lack of therapeutic efficacy  0  3  0  0
Damaged product  3  1  1  0
Other  1  3  7  11
Potential counterfeit  *  1  1  0
Product usage  5  0  0  0
total 56 88 128 91
breakdown of Veterinary medicinal Product recalls from the irish market 2006 2007 2008 2009
Packaging and/or labelling  1  2  10  0
Stability  1  0  0  0
Non-compliance with VPA  0  0  0  0
Sterility assurance and various other product safety concerns 0  0  0  0
Non-compliance with specification  0  2  0  0
Particulate or other contamination  0  0  0  1
Product mix-up  0  0  0  0
Unauthorised product  0  4  2  7
Other  0  1  1  0
total 2 9 13 8
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The total number of packs of exempt medicinal 
products notified to the IMB was 847,238.
Non-compliances and clarifications during the year 
included: 
• Notification by two companies of the incorrect 
manufacturers’ name and address for a large number 
of products. The concerned companies were required 
to quarantine all affected products until the details 
were corrected. 
• Several wholesalers failed to register with the 
notification system during 2008. These were contacted 
and required to register during 2009 and to submit 
retrospective data relating to the exempt products they 
sourced during the intervening period. 
• Two companies that had failed to notify the receipt of 
certain exempt products over a prolonged period were 
required to notify the data retrospectively. 
• One company failed to adhere to an IMB instruction 
regarding the need to cease supply of an exempt 
product and was subsequently requested to recall any 
remaining packs. 
• Notifying companies were informed that centrally-
authorised medicinal products were not permitted to 
be supplied as exempt products.
Regulatory Compliance Inspections 
Regulatory compliance inspections are carried out at the 
premises of marketing authorisation holder companies, 
and are risk-based. These are considered to be key areas 
of activity pertaining to the marketing and advertising 
of medicinal products and are distinct from the IMB’s 
inspections of manufacturers and wholesalers. Three such 
inspections were carried out in 2009. Areas of activity 
that have a high potential to impact on the quality, safety 
and the safe use of medicinal products were focussed on 
during these inspections. 
A detailed review of the quality defect and recall 
programme was performed with a view to identifying 
further risk-based process improvements and efficiency 
gains. A restructuring of the Market Compliance section 
resulted from this review, with the Quality Defect and 
Recalls Manager overseeing the day-to-day running of 
the programme and also the exempt medicinal products 
programme. 
Exempt Medicinal Products Programme
Under the medicinal product regulations governing 
placing on the market and wholesale distribution and 
manufacture, wholesalers and manufacturers are obliged 
to provide certain information to the IMB in relation 
to their sourcing and supply of unauthorised medicinal 
products. This is done online and 2009 was the first full 
year of operation for this notification scheme. Since 
January 2009, the required information must be provided 
to the IMB within two working days of receipt of exempt 
products. The main purpose of receiving such information 
is to facilitate the effective recall of any defective exempt 
medicinal products from the Irish market.
During 2009, 18,038 product lines were notified, 
compared with 13,941 product lines notified for 2008 
(mid-February to December). (Note: a figure of 16,000 
product lines was reported in error in the 2008 Annual 
Report). 
The total number of packs of exempt medicinal products 
notified to the IMB was 847,238. This compares to 
504,647 packs for 2008. While not all wholesalers were 
registered with the notification scheme during 2008,  
the IMB is concerned by the increase in volume and the 
overall extent of supply of exempt medicinal products, 
and continues to monitor the situation. 
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The Enforcement section initiated 3,729 
enforcement cases involving breaches of medicinal 
product legislation, an increase of 19%.
compliance
Aside from advertisements that were reviewed during 
regulatory compliance inspections, approximately 260 
were reviewed in–house. A particular focus is to ensure 
that the advertisement is consistent with the summary 
of product characteristics and promotes the rational 
use of the product. A number of non-compliances were 
identified and each was followed up with the marketing 
authorisation holder/company responsible for marketing.
ENFORCEMENT
Overview
During the reporting year, the Enforcement section 
initiated 3,729 enforcement cases involving breaches of 
medicinal product legislation, compared with 3,037 cases 
initiated in 2008. This represents a year-on-year increase 
of 19%. The majority were mail order importations of 
prescription-only medicinal products, continuing the 
trend from 2008.
A total of 494,502 tablets or capsules were detained, an 
increase of 39% over 2008. In addition, 1,650 packs of 
liquids, 449 packs of creams and 3,582 packs of assorted 
products were detained. Products detained included 
the following active substances: diazepam, zopiclone, 
sildenafil citrate, tadalafil (and other actives indicated for 
treatment of erectile dysfunction) rimonabant, finasteride, 
testosterone, amoxicillin, other antibiotics, corticosteroids 
and weight loss products, some of which contained 
sibutramine.
The majority of unauthorised medicinal products supplied 
into Ireland originated from India.
Medicinal products destroyed during the year in 
compliance with the Waste Management Acts 1996–2001 
amounted to 2,601 kg compared to 1,902 kg in 2008.
These included:
• Implementation of safety-related changes to product 
information and product labelling in the marketplace.
• Management and communication of regulatory 
commitments and regulatory changes.
• Management of registered product information.
• Provision of a medical information service for 
healthcare professionals.
• Quality management system in place at the companies 
to facilitate regulatory compliance.
• Medicinal product advertising activities.
The inspections identified a number of non-
compliances in the above areas and the IMB oversaw 
the implementation of the necessary corrective and 
preventative actions.
Advertising Compliance Programme
While the IMB has dealt for several years with issues 
relating to the advertising of medicinal products for 
human use, a formal advertising compliance programme 
was established in May 2009 within the Market 
Compliance section.
The programme is based on the Medicinal Products 
(Control of Advertising) Regulations, 2007 and is closely 
aligned with the regulatory compliance inspections 
referred to in the preceding section.
The programme is almost entirely risk-based and formal 
risk-criteria are used when selecting advertisements 
and companies for compliance monitoring. It includes 
proactive and reactive (e.g. complaints) elements. 
Randomly selected advertisements are included.  
The programme recognises where self-regulation, 
consistent with those parts of voluntary codes approved 
by the Minister for Health and Children, may be effective 
and is designed to avoid duplication of effort.
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During the year, IMB enforcement officers, 
customs officers and An Garda Síochána carried 
out a number of joint operations.
Ltd., a wholesale company, were found guilty on a total 
of eleven charges. These include retail and wholesale 
supply, and mail order supply through an internet website, 
of prescription-only medicinal products. Mr. Wesley Rea, 
director of both companies, and his two companies were 
ordered to pay €5,000 in costs to the IMB, fines of a 
further €1,000 and a donation of €4,000 to charity. An 
order for destruction of all products detained, valued at 
€32,000 (approx), was granted to the IMB. 
Analysis of enforcement cases
Planning
The planning section is responsible for planning activities 
across the department and works closely with the other 
four sections in this regard. It has a role in collating 
training and liaises with the IMB’s central learning and 
development section and is also responsible for reporting 
on all departmental activities.
The main focus of the planning section related to the 
compilation of the inspection programme for 2009 and 
the development, in conjunction with the Information 
Technology and Change Management department,  
of a workflow system for Compliance.
The IMB liaises with other enforcement agencies both 
nationally and internationally to stem the unauthorised 
flow of illegal medicinal products and medical devices 
into and out of Ireland. During the year, IMB enforcement 
officers, customs officers and An Garda Síochána carried 
out a number of joint operations. These included joint 
operations under Operation Pangea II in November 2009, 
a global initiative to identify and act against illegal websites 
supplying counterfeit and illegal medicinal products.
Enforcement carried out additional monitoring on 1,619 
mail order cases. These represented some 40% of all such 
cases. Information gained on the supplying websites 
enabled the IMB to eliminate duplicating websites and 
to identify 1,009 websites which had supplied medicinal 
products to Irish residents. These websites were reported 
to LegitScript, a US-based organisation which facilitates 
the closing down of ‘rogue internet pharmacies’ by 
working with the ICANN, the international governing 
body for the internet. Together they compel the registrar, 
or the internet service provider hosting the website, to 
display correct details of who owns the site. Many of the 
websites had concealed their true identities. 
Prosecutions relating to breaches of medicinal product 
legislation were taken in the Circuit Court and District 
Court. In February, a businessman, Mr. Michael Kehoe,  
was prosecuted by the Director of Public Prosecutions 
in the Circuit Criminal Court, Dublin for the sale and 
supply of prescription-only medicinal products, including 
ephedrine, and anabolic steroids. Mr. Kehoe pleaded guilty 
to three charges. The Court imposed fines of €2,000 on 
each of the three charges and granted an order to the  
IMB for destruction of the 80,000 tablets seized, which 
were valued at €80,000. Destruction costs of €3,000  
were awarded to the IMB.
At the District Court in Dolphin House in December, 
Nutrition Connection Ltd., trading as retail outlets in 
Capel Street Dublin and Tallaght, Dublin, and Future Pack 
Mail Order/
Internet 3606
Advertising 23
Retail 72
Counterfeit 13
Wholesale 4
Others 11
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CHANGE MANAGEMENT 
The Irish Medicines Board has a well established change 
management programme since 2003, with a strong focus 
on continuous improvement.
In March 2009, following a comprehensive review project, 
a new organisational structure was implemented to 
support the management of safety and licensing activities. 
One department (Human Products Authorisation and 
Registration) will now focus on licensing and registration 
activities for all products for human use, while the second 
department (Human Products Monitoring) will focus 
essentially on safety matters for human products. ‘Human 
Products’ refers to both pharmaceuticals and medical 
devices. 
The organisational commitment to continuous 
improvement was further strengthened by the adoption 
of ‘Lean Sigma’ methodology for a number of projects. 
In the second half of 2009, the organisation initiated its 
first ‘Lean Sigma’ project in response to the introduction 
of new legislation relating to medicinal product licensing. 
This project ran for a 12 week period and was approved 
in November 2009. An ambitious work programme has 
been designed for 2010 to deliver on the opportunities 
identified during the project. Eight projects will operate 
in 2010 with a strong focus on delivering quality and 
business efficiencies. 
The IMB provides internet-based services to a variety 
of stakeholders. These applications range from online 
adverse reaction reporting to online application systems. 
In 2009, support was provided to over 230 staff, with 
additional support and training provided to over 500 
external users of IMB systems. External users requiring 
IT support services are predominantly based within the 
medical devices and pharmaceutical sector. 
Organisational access to high quality IT services is a key 
factor in delivering efficient and effective deliverables 
to stakeholders. In 2009, the organisation continued 
its investment in solutions in order to deliver on its 
regulatory commitments.
Support was also provided to a number of external bodies, 
including the Office of Tobacco Control, and regulatory 
bodies in Malta and Norway. 
The IT and Change Management function has four work 
streams:
information technology  
and change management
The IT and Change Management department delivers specialist business analysis, information technology and 
telecommunications services throughout the organisation. Business process improvement skills are also sourced  
from this area, reflecting the organisation’s commitment to the agenda of transformation in the public sector.
Infrastructure
Management
Support &
Training
Project
Management
Change
Management
ms. Suzanne mcdonald  Director of Information Technology and Change Management
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A new organisational structure was 
implemented to support the management of 
safety and licensing activities.
and good manufacturing practice are ongoing, and will 
continue to influence the design of technology solutions 
both at the IMB and across the EU regulatory network.
During 2009 the IMB was influential in all aspects 
of the EU Telematics Programme. In mid-2009, the 
EMA Management Board Telematics Committee was 
established and the IMB is represented on this group. 
EU Telematics Programme Architecture consists of the 
following elements and further information on these  
can be found at www.eudra.org.
• EudraVigilance (Drug Safety)
• EudraPharm (Medicinal Product Information)
• EudraGMP (Good Manufacturing Practice)
• EudraCT (Clinical Trials)
• EudraNet (Secure network communications)
• CTS (Mutual Recognition/Decentralised Procedure 
Application Tracking)
• EU Datawarehousing /Reference Data Modelling
INFORMATION TECHNOlOGY
EU Telematics Programme
The EU Telematics Programme is a key component in  
the IMB’s strategy for managing regulatory information. 
At European level, and managed through the EMA, the 
EU Telematics Programme covers all aspects of medicinal 
product licensing and post-marketing activities. Fifty-
one national Competent Authorities are linked to the 
EudraNet system spanning all Member States, and 
providing a secure communication channel for the 
regulatory network.
The EU Telematics Master Plan covers a five year period, 
and seeks to establish standards for communication and 
exchange of information between industry and regulators. 
In this context, projects relating to electronic submissions 
(eCTD) and pharmacovigilance (EudraVigilance) are 
ongoing both at national Competent Authority level 
and at a centralised level via the EMA. A range of other 
projects, including systems to support clinical trial tracking 
Lean Sigma Methodology used to streamline variation application management
Define
Measure
Analyse
Improve
Control
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Over 77,000 individuals visited the website 
in 2009 with over 1.5 million pages 
viewed.
information technology and change management
Compliance and Safety Solutions
Technology to assist in compliance activities was further 
developed in 2009. New applications to provide improved 
planning and management of inspection-related 
functions were at an advanced stage by the end of 2009. 
Further developments to support market surveillance, 
controlled drugs, and good distribution practice activities 
are also underway. 
The IT function also worked closely with the Human 
Products Monitoring department on the development 
of the new safety monitoring system. This system 
provides superior case management and signal detection 
capabilities. It is scheduled to go into operation in 2010.
Document Management
A project to scan legacy documentation was commenced 
in late 2009. This initiative will result in the transfer of 
over two million pages to the IMB systems and will enable 
IMB staff to access data efficiently in the course of their 
activities. The introduction of European standards for the 
receipt and evaluation of applications is also contributing 
to a reduction in the volume of paperwork associated with 
the licensing of medicines. 
Future Developments
The IMB plans to develop a new three-year IT strategy 
in 2010. This strategy will reflect the business objectives 
and will focus on delivering benefits to the stakeholders. 
The requirement for an improved website servicing a 
broader audience has been identified and this will be 
addressed as part of the strategy. Other initiatives include 
the further development of web-based applications across 
all activities, while working with other EU regulators to 
identify common solutions and services for stakeholders. 
Systems to manage the regulation of cosmetics will also 
form part of the new IT strategy.
Web-Based Services
In 2009, the Irish Medicines Board website www.imb.ie
received a substantially higher volume of visitors than 
any other year. Over 77,000 individuals visited the website 
in 2009 with over 1.5 million pages viewed. The target 
audience was largely EU based – Ireland and the UK –  
with a significant number of visitors from North America. 
A substantial part of the activity can be attributed to the 
publication of Pandemic H1N1-related information on 
the website and the facility to report adverse reactions 
associated with the vaccination programme. The listing 
of licensed human medicines continues to be the most 
popular section of the site, consistent with prior years.
The IMB now routinely publishes all safety notices via the 
IMB website, with the facility for notification to registered 
users via e-mail or SMS. The website also provides 
online forms to facilitate reports on adverse reactions 
to medicines, potential quality defects and incidents 
relating to medical devices, tissues and cells. Users are 
encouraged to register on the website and to utilise the 
reporting forms wherever possible. We received very 
valuable assistance from users in 2009 and we encourage 
website visitors to send their comments or suggestions 
for improvement to helpdesk@imb.ie.
Extranet services continue to play a large part in delivering 
services to stakeholders. The online tracking and 
application system (RIO) remains a key system for the 
pharmaceutical industry. RIO provides a mechanism to 
track the progress of applications and also to make online 
applications. The introduction of changes in legislation 
will result in substantial changes to the RIO system in early 
2010, and it is planned to extend the services following the 
successful implementation of these changes. RIO is a free 
service to the pharmaceutical industry and its agents, and 
the IMB encourages use of the system, wherever possible. 
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During November and December, support was provided to 
the Human Products Monitoring department in relation 
to IMB communications on the influenza pandemic,  
a number of new consumer leaflets on human medicines 
were developed for publication in 2010, and work was 
undertaken for market research to be carried out early  
in 2010.
BuSINESS CONTINuITY
The Chief Executive’s Office was responsible for business 
continuity planning for the influenza pandemic, ensuring 
that plans were current and appropriate to the expected 
impact on operations and that guidance was issued to 
staff. While the workload of a number of departments 
had significant input in the licensing, pharmacovigilance 
and market compliance issues relating to the vaccination 
campaign, the overall effect on routine operations was 
manageable.
QuAlITY MANAGEMENT
During 2009, a substantial increase in the implementation 
of the quality system was achieved. At the end of the year, 
74% of the total expected implementation was in place, 
up from 49% at the end of 2008. 
There was a significant increase in internal audits in 2009. 
17 audits were conducted on 21 processes by auditors 
from the QMS section and from across the IMB. Most 
audits were of authorisation processes as these constitute 
a large proportion of processes undertaken by the IMB. 
chief executive’s  
office
The complaints procedure and the fire drill procedure 
were also audited. Audit objectives were widened this year 
to include not only conformance to procedures but also 
process performance. At the end of the year, most audits 
were either closed out or had target completion dates for 
corrective actions in early 2010.
Management review of the system took place in March. 
Updates were sent to all staff on an ongoing basis, 
including notifications of new and revised documents,  
and induction training was carried out for new staff. 
BENCHMARkING OF EuROPEAN MEDICINES 
AGENCIES 
The IMB received a visit from benchmarking assessors 
in May 2009, as part of the BEMA programme under 
the HMA in the EU. The assessors came from medicines 
agencies in the UK, France and Greece and spent a week 
reviewing the IMB’s performance in relation to defined 
standards of best practice. These standards have been 
developed by the HMA in the areas of management, 
assessment, pharmacovigilance and inspections.  
At the end of the week, they presented the report of their 
findings and their overall conclusions. In particular, they 
identified the following areas of significant strength:
• Positive leadership provided by the Board and 
Management Committee, supported by a 
comprehensive communication programme  
for individuals and teams which promotes the  
agency’s values.
The Office took over management of the content and updates to the IMB website in March 2009. In November, a specific 
communications function was established within the Office, with the aim of developing the IMB’s communications, 
information and education role and a more co-ordinated, professional and consistent approach to communications  
with all stakeholders. 
dr. mike morris  Senior Scientific Advisor dr. caitríona Fisher  Quality Manager
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17 internal audits were conducted on 21 
processes by auditors from the QMS section and 
from across the IMB.
SENIOR SCIENTIFIC ADVISOR
Borderline Product Classification
The IMB provides a service to stakeholders to assist in 
clarifying whether products should be categorised as 
medicinal products and medical devices and thereby fall 
under the remit of the IMB from a regulatory perspective 
or whether they are outside the scope of the IMB’s 
remit. Queries are routinely received in regard to human 
medicinal products, veterinary medicinal products and 
medical devices and in each of the three areas, relevant 
personnel within the organisation have provided an 
IMB decision on request as to the status of a given 
product. This service in each of the three areas has been 
standardised under the quality management system.
A classification service is operated for products which are 
on the borderline of human medicines and other products 
such as food supplements, cosmetics and medical devices. 
Requests for classification, whether external or internal, 
are ultimately presented to an internal, multi-disciplinary, 
human medicinal product Classification Committee 
which meets once a month. The Committee consists of 
appropriately experienced staff from the Human Products 
Authorisation and Registration, Compliance and Human 
Products Monitoring departments and is chaired by  
Dr. Mike Morris, Senior Scientific Advisor.
The outcome of the decision is conveyed promptly 
to the enquirers and in turn is accompanied by a 
recommendation for any action arising depending 
upon the circumstances. In the event of an appeal to the 
Classification Committee decision, the matter can be 
referred to the Advisory Committee on Human Medicines 
for arbitration. Full details of the procedure can be found 
in the ‘Guide to the Definition of a Medicinal Product’ 
which can be found on the IMB website. 
chief executive’s office
• Focus on continuous improvement.
• Significant contribution to other Competent 
Authorities via the HMA meetings and associated 
working parties. 
• Support given by HR to the organisation with a clear 
and effective performance management system 
which strives for high performance while at the same 
time supporting the individual in whatever form is 
necessary. 
• Varied and substantial opportunities for staff to 
develop their skills and competencies. 
• Integration of the quality system into the organisation, 
its support to the business of the IMB and the value  
it adds.
• Organisation’s change management competence in 
planning and responding to change.
• Significant investment in IT systems to support 
business needs.
A small number of opportunities for improvement were 
also identified for review and implementation.
The IMB co-chairs and participates in the Steering Group 
for the second cycle of BEMA. During 2009, the BEMA 
secretariat at the IMB provided support to the assessors 
and agencies which were visited during the year, and 
organised a seminar at the EMA for assessors and agency 
staff to review current issues and opportunities with the 
programme. Training for a small number of new assessors 
was also arranged at the EMA. At the end of 2009,  
18 visits to EU medicines agencies had taken place,  
with the remainder scheduled for 2010 and 2011.
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EuROPEAN PHARMACOPOEIA
Three meetings of the European Pharmacopoeia (Ph. Eur.) 
Commission were held in 2009 and were attended by  
Dr. Mike Morris and Mr. Mirza Catibusic. In addition, 
delegates from Ireland participated in some of the many 
groups of experts and working parties which provide 
expert advice to Ph. Eur. Group 13B on Herbal Medicines 
met three times in 2009; Ireland is represented by  
Dr. Des Corrigan.
The Process Analytical Technology (PAT) working party 
held three meetings in 2009, and made useful progress 
in developing a new policy on uniformity testing of large 
sample sizes and in revision of the Ph. Eur method for  
NIR analysis.
The Homeopathic Manufacturing Methods (HMM) and 
Homeopathic Products (HOM) Working Parties met twice 
in 2009 including a visit to manufacturers. These visits 
were very helpful in moving towards consensus in the 
monographs on homeopathic substances.
Dr. Mike Morris participates in the work of the above 
groups and working parties.
The IMB Classification Committee (human medicines) 
met 10 times in 2009 and considered a total of 131 new 
products. In addition, there were 24 products revisited 
from pre-2009. The majority of the new applications were 
internal (114) emanating mainly from the Compliance 
department, with 17 external applications.
The Classification Committee continues to work closely 
with representatives of the Market Compliance section, 
which is represented on the Committee, and also the 
Enforcement section. Externally, there is also a very close 
working relationship with the Food Safety Authority 
of Ireland and a number of referrals were made in both 
directions during the course of 2009. The committee 
also engaged in regular dialogue with the Department 
of Health and Children and also with the Advertising 
Standards Authority of Ireland. 
The table below gives the figures for classification queries 
for 2009 compared with previous years.
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The IMB Classification Committee (human 
medicines) met 10 times in 2009 and 
considered a total of 131 new products.
Classification queries 2007-2009
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An internal multi-disciplinary group was 
established to prepare for the implementation 
of the Advanced Therapies Regulation.
Senior Scientific advisor
During 2008, an internal multi-disciplinary group was 
established in the IMB to prepare for the implementation 
of the legislation. This group is chaired by the Senior 
Scientific Advisor and continued to meet during 2009.  
In February 2009, an information meeting was held at the 
IMB offices on the subject of the new ATMP legislation. 
IMB experts and staff and invited experts, mainly from 
clinical practice, attended this meeting and various 
presentations were made by IMB staff on the likely impact 
of the new legislation. In particular, it was emphasised that 
advanced therapies prepared in hospitals for individual 
patients will be exempt from the marketing authorisation 
requirements, but such activities will still be subject to 
a manufacturer’s authorisation. The CAT held its first 
meeting in 2009 and continues to meet on a monthly 
basis at the EMA offices in London.
VARIATIONS
The new EU guidelines on classification of variations 
and best practice were published for consultation during 
summer 2009 and will be finalised in 2010. The internal 
IMB group continued to meet to provide comments on 
the consultation, review the likely impact on workload 
and finances and to look at the EU application form in 
the context of the likely impact on the IT needs of the 
organisation. An information day is planned for early 2010.
ADVANCED THERAPIES
The Advanced Therapies Regulation (EC) 1394/2007 
became effective on 1 January 2009. This regulation deals 
with gene therapy, cell therapy and tissue-engineered 
medicinal products and brings these specialised products 
under the definition of a medicinal product given in 
Article 1 of Directive 2001/83/EC as amended. The 
directive was itself further amended in September 2009 
by Commission Directive 2009/120/EC to change the 
definitions and dossier requirements for marketing 
authorisation for these highly specialised advanced 
therapy medicinal products (ATMPs). Applications for 
marketing authorisations for ATMPs will proceed via the 
EU centralised procedure as laid down in Regulation (EC) 
726/2004 from 1 January 2009. The regulation sets up 
a specialised Committee on Advanced Therapies (CAT) 
within the EMA. The committee has one member and one 
alternate member from each Member State and staff from 
the IMB have been appointed to this committee.
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The IMB’s ‘green team’ continued to look at all 
consumables in the organisation and implemented 
some plans for reducing consumption and costs for the 
organisation.
The Corporate Affairs section provided support to the 
Veterinary Information Day on 8 September, which 
was well attended by industry. During 2009, extensive 
preparation was conducted for the BT Young Scientist 
event and four other events scheduled to take place at the 
beginning of 2010. 
The IMB published three Medicinal Products Newsletters 
in 2009, issue numbers 32, 33 and 34. The newsletters 
cover a wide range of topics such as:
• electronic reporting for adverse reactions
•  direct healthcare professional communications
• guide to electronic submissions of applications for 
authorisations and registrations of human medicines
• herbal medicinal products
• GMP updates
• new system for controlled licences
FINANCE 
As outlined in the financial statements, the IMB’s finances 
remained stable. The Accounts section continued to 
successfully manage the high volumes of work while 
maintaining high standards of internal control. To further 
increase efficiency and make a contribution towards a 
greener environment, the section commenced paying 
staff expenses directly into bank accounts during the  
year, replacing the previous method of payment by 
cheque. In addition, customer statements are now being 
e-mailed out on a monthly basis. A detailed review of the 
IMB’s fee structure also took place during the year.  
In 2009, internal auditors reviewed the areas of 
purchasing and procurement. All procedures were carried 
out using standard operating procedures under the quality 
management system which has added great value to the 
operation of the section.
CORPORATE AFFAIRS
2009 was a busy year for corporate services as the 
increases in operations outlined in all the other 
departments increased the level of services provided. 
Finance and  
corporate affairs
The Finance and Corporate Affairs department delivers a number of key service areas to the organisation. These include:
• Management and safeguarding the finances of the IMB
• Providing secretarial support to the Board and Committees and ensuring adherence to best practice in the area  
of corporate governance
• Managing the building and accommodation requirements of the IMB
• Providing infrastructure requirements for the staff and visitors, reception, canteen, travel service, and library services
• Managing the Freedom of Information obligations
• Managing legal issues for the IMB
2009 was another challenging and busy year for the department and some of the highlights are outlined below.
ms. rita Purcell  Director of Finance and Corporate Affairs
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The IMB received 18 Freedom of Information 
Act requests in 2009.
Finance and corporate affairs
• Braille and patient-accessible leaflets
• revised format for manufacturer’s/importer’s 
authorisation
• veterinary pharmacovigilance
• veterinary regulatory fee consultations
There were a number of Freedom of Information Act 
requests in 2009. The IMB received 17 non personal 
requests and one personal request for information.  
The outcome of these requests is outlined below:
request outcome
Number of FOI requests received 18
Granted/ part granted  11
Refused 6
Withdrawn/handled outside FOI Act 1
Internal reviews 0
Appeals to the Information Commissioner 0
BuIlDINGS
2009 continued to be a busy year in the buildings area  
in relation to ongoing maintenance of the IMB offices.  
A number of internal buildings projects were undertaken 
to maximise space utilisation and workflow efficiency.
 Annual Report 2009 59
Staff breakdown by gender 2009
The IMB has a range of family-friendly working 
arrangements which were supplemented by the 
introduction of a policy on part-time working in 2009. 
There are now 11% of staff availing of flexible working 
arrangements. 
Staff retention during 2009 remains strong, evidenced 
by turnover rates at 11.1% (including entry level 
administrative posts) and 3.8% (excluding entry level 
administrative posts). This is significantly below the 
industry average which ranges from 12.7 to 19.1%.
The HR department was involved during 2009 with other 
agency partners in the preparation of preliminary planning 
documents regarding the HR impact of the proposed 
merger of agencies.
ORGANISATION DEVElOPMENT
The HR department participated in an organisation-wide 
BEMA audit which acknowledged the effective people 
management practices in place within the IMB.
The age and gender profile of staff in the IMB remained 
unchanged in 2009. The majority of staff are between  
the ages of 20 and 40 with 75% female and 25% male. 
The organisation continues to be in compliance with  
the 3% target set by the Disability Act 2005.
Staff breakdown by age 2009
human resources
The HR department was established as a separate department and represented at executive level in 2009.  
The HR strategy is to work with the business identifying and implementing innovative solutions to address emerging needs. 
The key areas in which services are provided are:
• Organisation development • Employee relations
• Performance management and coaching • Recruitment and selection
• Learning and development 
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The number of internal training sessions in 
2009 increased by 20% from 2008.
human resources
ABSENCE MANAGEMENT
The overall absence rate for 2009 was 2.8% which was 
a notable decrease on 2008 (3.4%) particularly in the 
context of the expectation of increased absence levels due 
to the presence of the H1N1 flu pandemic. These rates are 
well below industry average rates of 3% to 4%. 
lEARNING AND DEVElOPMENT
This continued to be a vital element of the effective 
development of our human resources. Key areas of  
activity were:
• The HR department undertook a comprehensive review 
of the approach to the identification of learning and 
development needs and the delivery of solutions across 
the organisation. This was with a view to developing a 
learning and development strategy to put in place the 
systems and processes to ensure our human resources 
are effectively trained and developed to meet both 
current and future needs. This process was further 
supported by the appointment of a Learning and 
Development Manager at the end of 2009. 
• The average number of training days per person in 
2009 was just over three, continuing the trend set in 
2008. The nature of courses undertaken was broad as 
set out on the next page.
• The number of internal training sessions in 2009 
increased by 20% from 2008 based on a strong focus 
by the organisation on dignity and respect training and 
the implementation of training sessions for all staff 
and for those managing staff. A total of 21 sessions 
were delivered, six of which were specifically for those 
with responsibility for managing staff. 
PERFORMANCE MANAGEMENT AND COACHING
This is a priority area for the business and HR and a 
number of significant activities were undertaken in 2009:
Performance Development Programme (PDP)
In response to the introduction of a new business 
planning model, the PDP (whose purpose is to cascade 
such plans through the business to an individual job 
holder level) was redesigned and support material 
developed for roll out and implementation in early 2010.
Probation
The management of probation within the IMB is vital 
to ensure that only those staff members who have the 
required skills are retained and the HR department plays 
an active role in supporting line management in this 
process. In 2009, there were 87 employees (including  
new joiners and those acting up or promoted) due to 
complete their probation. Of these 74% completed 
probation successfully, 5% had probation extended and 
14% left during the period of probation. The probation 
period for the remaining 7% was ongoing.
SuPPORT FOR lINE MANAGEMENT
The HR department has as one of its key objectives 
the ongoing provision of support to managers in the 
effective management of their staff. In 2009, this was 
achieved through access as required to expert advice and 
assistance and the provision of statistical reports in a 
range of areas to assist in decision making. These included 
absence rates, flexitime, annual leave etc. In addition, the 
department delivered a range of training and coaching 
supports required as a result of the restructuring of the 
Human Medicines and Medical Devices departments and 
the creation of the new departments of Human Products 
Authorisation and Registration, and Human Products 
Monitoring.
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The overall absence rate for 2009 was 2.8%, 
well below industry average rates of 3% to 4%.
EMPlOYEE RElATIONS
2009 continued to reflect a stable industrial relations 
climate within the IMB. 
The staff communications group met regularly and each 
meeting was attended by a HR representative. This forum 
continues to facilitate communication of policy changes 
or planned initiatives and allows feedback directly from 
staff representatives from all departments.
Health and safety and wellness initiatives during the year 
2009 included eye tests, provision of seasonal flu vaccine, 
a walking challenge and a series of lunchtime learning 
sessions. The uptake on all initiatives was positive.
RECRuITMENT AND SElECTION
In 2009, 27 competitions took place including 
promotions, filling vacant existing posts and new 
appointments. The IMB website proved to be one of the 
most effective means of attracting candidates to technical 
posts.
Recruitment sources 2009
The IMB continues to support staff in undertaking 
programmes of further education with 7.6% of staff 
receiving support for courses.
Training courses broken down by type 2009
Qualification type
A new software module (Empowerment) was purchased 
to increase the functionality of the HR database and 
provide a workflow type system to enable an improved 
process for planning, approving, recording and reporting 
of training activities.
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Financial Statements
For the year ended 31 December 2009
board members and other information
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Ms. Maureen Windle
 The Board was appointed by the Minister for Health and Children  
for a term of 5 years from 1st January 2006.
Bankers : Allied Irish Bank
Lower Baggot Street 
Dublin 2
 Bank of Ireland Corporate 
Lower Baggot Street 
Dublin 2
Solicitors : Eugene F. Collins
Temple Chambers 
3, Burlington Road 
Dublin 4
Head Office : Kevin O’Malley House
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Earlsfort Terrace 
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Auditor : Comptroller and Auditor General
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The Irish Medicines Board (the IMB) was established under the terms of the Irish Medicines Board Act, 1995, and is 
governed by a Board which was appointed by the Minister for Health and Children. The Board of the IMB (the Board) 
consists of a chairman and seven unremunerated non executive members.
The IMB is committed to the highest standards of Corporate Governance and has implemented the Department of Finance 
“Code of Practice for the Governance of State Bodies”. This Code of Practice, which was issued to the Irish Medicines Board 
in January 2002, incorporates many of the principles under which the IMB operates, taking account of the size and legal 
nature of the organisation. 
An updated Code of Practice was published by the Minister for Finance in June 2009, to take account of administrative and 
legislative developments in the corporate governance framework since 2001. The IMB have carried out a detailed review  
of this updated Code, to ensure that its provisions are still reflected in the principles under which the IMB operates.
The IMB has in place an extensive Code of Conduct for all staff, committees and Board members. The IMB applies the 
highest standards of disclosure and transparency in respect of interests held by staff, committees and Board members.
Audit Committee
The IMB has an audit committee comprising two Board members, which met on 5 occasions during 2009. This committee 
is responsible for reviewing internal control matters, together with any other issues raised by the external auditors,  
the Board or management. The external auditor meets annually with the committee to brief them on the outcome of  
the external audit. In 2005 the IMB appointed Crowleys DFK as internal auditor to the Board under a three-year contract. 
During 2009 the internal auditors reviewed the areas of purchasing and procurement and reported their findings to the 
audit committee. The audit committee has also been involved with the review of the quality systems as described below.
Quality Systems
During 2009, the finance section of the IMB continued the process of implementing and reviewing standard operating 
procedures (SOPs) under the quality management system. This process involved a critical review and analysis of internal 
controls and processes throughout the section with particular emphasis on risk management. This system now underpins 
the internal control environment and feeds into the internal audit process and ultimately into the audit committee.
Remuneration Policy - Board Members and Executive Directors
Remuneration and travel expenses paid to Board members are disclosed in note 17 to the financial statements.  
The Chairman receives remuneration as directed by the Minister for Health and Children in accordance with the Irish 
Medicines Board Act, 1995. Other Board members receive travel expenses in accordance with circulars issued by the 
Department of Health and Children. The Chief Executive is remunerated in accordance with guidelines issued from 
Government and other Executive Directors are paid in accordance with Department of Health and Children pay scales. 
Remuneration Committee
The IMB has established a remuneration committee as a sub-committee of the Board to review the remuneration of the 
Chief Executive in accordance with guidelines issued by the Department of Finance and the Department of Health and 
Children. The Chief Executive’s remuneration is disclosed in note 18 to the Financial Statements.
Internal Control
The Board is responsible for the IMB’s systems of internal control. Such systems can only provide reasonable and not 
absolute assurance against material misstatement or loss. The systems of internal controls in use in the Irish Medicines 
Board are described more fully in the Chairman’s report on page 64.
corporate governance
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report of the chairman of the irish medicines board 
regarding the assessment of internal financial controls of a State body for the year ended 31st December 2009
1. I, as Chairman, acknowledge that the Board is responsible for the body’s system of internal financial control.
2. The IMB system of internal control can provide only reasonable and not absolute assurance against material error, 
misstatement or loss.
3. The Board confirms that there is an ongoing process for identifying, evaluating and managing the significant risks faced 
by the IMB. This process is regularly reviewed by the Board via the report of the Chief Executive.
 Management are responsible for the identification and evaluation of significant risks applicable to their areas of business 
together with the design and operation of suitable internal controls. These risks are assessed on a continuing basis and 
may be associated with a variety of internal or external sources including control breakdowns, disruption in information 
systems, natural catastrophe and regulatory requirements.
 Management reports fortnightly on operational issues and risks and how they are managed to the Management 
Committee. The Management Committee’s role in this regard is to review on behalf of the Board the key risks inherent 
in the affairs of the IMB and the system of actions necessary to manage such risks and to present their findings on 
significant matters via the Chief Executive to the Board.
 The Chief Executive reports to the Board on behalf of the executive management on significant changes in the work 
of the IMB and on the external environment, which affects significant risks. The Director of Finance and Corporate 
Affairs provides the Board with monthly financial information, which includes key performance indicators. Where areas 
for improvement in the system are identified the Board considers the recommendations made by the Management 
Committee.
 An appropriate control framework is in place with clearly defined matters which are reserved for Board approval only or, 
as delegated by the Board, for appropriate Executive approval. The Board has delegated the day-to-day management 
of the IMB and established appropriate limits for expenditure authorisation to the Executive. The Chief Executive is 
responsible for implementation of internal controls, including internal financial control.
 The system of internal financial control is monitored in general by the processes outlined above. In addition, the Audit 
Committee of the Board reviews specific areas of internal control as part of their terms of reference.
4. The Audit Committee of the Board have satisfactorily reviewed the effectiveness of the system of internal control on 
behalf of the Board. The Audit Committee of the Board carried out a formal review of these systems in respect of 2009 
at its meeting on 18th June 2010.
 
Pat O’Mahony 
Chairman
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The Board is required by the Irish Medicines Board Act, 1995 to prepare financial statements for each financial year which 
give a true and fair view of the state of affairs of the Irish Medicines Board and of its surplus or deficit for that period.
In preparing those statements the Board is required to:
• select suitable accounting policies and apply them consistently
• make judgements and estimates that are reasonable and prudent
• disclose and explain any material departures from applicable accounting standards, and
• prepare the financial statements on a going concern basis unless it is inappropriate to presume that the Irish Medicines 
Board will continue in existence.
The Board is responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the 
financial position of the Irish Medicines Board and which enable it to ensure that the financial statements comply with 
the IMB Act and with accounting standards generally accepted in Ireland. It is also responsible for safeguarding the assets 
of the Irish Medicines Board and hence for taking reasonable steps for the prevention and detection of fraud and other 
irregularities.
 
On behalf of the Board
 
Pat o’mahony maureen Windle 
Chairman Board Member
Statement of board members’ responsibilities
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I have audited the financial statements of the Irish Medicines Board for the year ended 31 December 2009 under Section 18 
of the Irish Medicines Board Act, 1995.
The financial statements, which have been prepared under the accounting policies set out therein, comprise the Accounting 
Policies, the Statement of Income and Expenditure, the Statement of Total Recognised Gains and Losses, the Balance Sheet, 
the Cash Flow Statement and the related notes.
Respective Responsibilities of the Board and the Comptroller and Auditor General
The Irish Medicines Board is responsible for preparing the financial statements in accordance with the Irish Medicines Board 
Act, 1995, and for ensuring the regularity of transactions. The Board prepares the financial statements in accordance with 
Generally Accepted Accounting Practice in Ireland as modified by the directions of the Minister for Health and Children in 
relation to accounting for superannuation costs. The accounting responsibilities of the Board Members are set out in the 
Statement of Board Members’ Responsibilities. 
My responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements and 
International Standards on Auditing (UK and Ireland).
I report my opinion as to whether the financial statements give a true and fair view, in accordance with Generally Accepted 
Accounting Practice in Ireland. I also report whether in my opinion proper books of account have been kept. In addition,  
I state whether the financial statements are in agreement with the books of account.
I report any material instance where moneys have not been applied for the purposes intended or where the transactions do 
not conform to the authorities governing them.
I also report if I have not obtained all the information and explanations necessary for the purposes of my audit.
I review whether the Statement on Internal Financial Control reflects the Board’s compliance with the Code of Practice for 
the Governance of State Bodies and report any material instance where it does not do so, or if the statement is misleading 
or inconsistent with other information of which I am aware from my audit of the financial statements. I am not required to 
consider whether the Statement on Internal Financial Control covers all financial risks and controls, or to form an opinion 
on the effectiveness of the risk and control procedures.
I read other information contained in the Annual Report, and consider whether it is consistent with the audited financial 
statements. I consider the implications for my report if I become aware of any apparent misstatements or material 
inconsistencies with the financial statements.
Basis of Audit Opinion
In the exercise of my function as Comptroller and Auditor General, I conducted my audit of the financial statements in 
accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practices Board and by 
reference to the special considerations which attach to State bodies in relation to their management and operation.  
An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures and regularity of the 
financial transactions included in the financial statements. It also includes an assessment of the significant estimates and 
judgments made in the preparation of the financial statements, and of whether the accounting policies are appropriate to 
the Board’s circumstances, consistently applied and adequately disclosed.
I planned and performed my audit so as to obtain all the information and explanations that I considered necessary in order 
to provide me with sufficient evidence to give reasonable assurance that the financial statements are free from material 
misstatement, whether caused by fraud or other irregularity or error. In forming my opinion I also evaluated the overall 
adequacy of the presentation of information in the financial statements.
report of the comptroller and auditor general 
for presentation to the Houses of the Oireachtas
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Opinion
In compliance with the directions of the Minister for Health and Children, the Board recognises the costs of superannuation 
entitlements only as they become payable. This basis of accounting does not comply with Financial Reporting Standard 17 
which requires such costs to be recognised in the year the entitlements are earned. 
Except for the non-recognition of the Board’s superannuation costs and liabilities in accordance with Financial Reporting 
Standard 17, the financial statements give a true and fair view, in accordance with Generally Accepted Accounting Principles 
in Ireland, of the state of the Board’s affairs at 31 December 2009 and of its income and expenditure for the year then 
ended.
In my opinion, proper books of account have been kept by the Board. The financial statements are in agreement with the 
books of account.
gerard Smyth 
For and on behalf of the Comptroller and Auditor General 
10 September 2010
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Historical Cost Convention
The Financial Statements are prepared in accordance with generally accepted accounting principles under the historical cost 
convention and comply with the financial reporting standards of the Accounting Standards Board, with the exception of 
superannuation - see note below.
Income Recognition
Income is recognised in the financial statements on the following basis:
• In the case of applications for product authorisations (new applications, variations to existing authorisations, or 
transfers) and clinical trial applications, income is recognised in the financial statements when a valid application form  
is received. 
• In the case of wholesale and manufacturing licences and maintenance of product authorisations, fees are payable 
annually and a full year’s income is accrued in each financial year.
Expenditure Recognition
Expenditure is recognised in the financial statements on an accruals basis as it is incurred.
Reporting Currency and Currency Translation
The financial statements are prepared in euros.
Transactions in currencies other than euro are recorded at the rates ruling at the date of the transactions or at a contracted 
date. Monetary assets and liabilities are translated into euro at the balance sheet date or at a contracted date. Exchange 
differences are dealt with in the income and expenditure account. 
Tangible Assets
Tangible Assets excluding Premises
Tangible assets excluding premises are stated at cost less accumulated depreciation. Depreciation is calculated in order 
to write off the cost of tangible assets to their estimated residual values over their estimated useful lives by equal annual 
instalments.
The estimated useful lives of tangible assets by reference to which depreciation has been calculated are as follows:
leasehold Property : Unexpired portion of the lease
Fixtures and Fittings :  5 years
Computer Equipment :  3 years
Improvements to Premises : 10 years
Premises
The IMB purchased its premises at Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2 on 22 December 2004. 
The value capitalised was equal to the purchase price plus those costs directly attributable to bringing the asset into use.
No depreciation has been calculated on the value of premises, as the remaining useful economic life is estimated to be 
greater than 50 years.
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Taxation
The Irish Medicines Board is exempt from liability to Corporation Tax under Section 32 of the Finance Act, 1994.
Debtors
Known bad debts are written off and specific provision is made for any amount the collection of which is considered 
doubtful. 
Superannuation
The superannuation scheme operated by the Irish Medicines Board is in accordance with the Local Government 
(Superannuation Revision) (Consolidation) Scheme, 1986. It is an unfunded statutory scheme and benefits are met from 
current income as they arise.
The charge to salaries and wages is stated gross of superannuation deductions of €629,478 (2008 – €637,517). The surplus 
for the year on page 70 is then shown both before and after superannuation transactions for the year. The income and 
expenditure reserve on the balance sheet is split between retained reserves and superannuation reserves in note 11.
By direction of the Minister for Health and Children, the provisions of FRS 17 are not being complied with. 
Provisions
A provision is recognised when the IMB has a present obligation as a result of a past event, it is probable that this will be 
settled at a cost to the IMB and a reliable estimate can be made of the amount of the obligation.
Library
No value has been placed on the books, audio-visual resources and electronic databases in the library. Expenditure on these 
items is written off in the year in which it is incurred.
Leases
All leases are treated as operating leases and the rentals thereunder are charged to the Income and Expenditure account on 
a straight line basis over the lease period.
  note  2009  2008 
   €  €
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Fee Income  2  21,453,656   18,704,256 
Other Income 3  4,713,275   5,220,407 
    26,166,931   23,924,663 
Salaries and Wages 4  15,869,204   15,255,687 
Other Operating Costs 5  5,489,743   5,888,006 
Depreciation 1  1,502,168   1,606,304 
    22,861,115   22,749,997 
Surplus for the year before write back of Superannuation contributions   3,305,816   1,174,666 
Staff Superannuation Contributions   629,478   637,517 
Surplus for the year   3,935,294   1,812,183 
Balance brought forward   14,487,130   12,674,947 
Balance carried forward  18,422,424   14,487,130 
All income and the surplus for the year arises from continuing activities.   
 
Pat o’mahony maureen Windle 
Chairman Board Member
The accounting policies on pages 68 to 69 and the notes on pages 74 to 80 form part of the financial statements.
Statement of income and expenditure
For the year ended 31 December 2009
  note  2009  2008 
   €  €
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Retained Surplus for the year   3,935,294  1,812,183
Unrealised Gains for the year   -   - 
Total Recognised Gains   3,935,294  1,812,183
The accounting policies on pages 68 to 69 and the notes on pages 74 to 80 form part of the financial statements.
Statement of total recognised gains and losses 
For the year ended 31 December 2009
  note  2009  2008 
   €  €
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balance Sheet
As at 31 December 2009
Tangible Assets 1  24,194,544   24,684,505 
Current Assets   
Debtors and Prepayments 6  2,082,648   1,664,448 
Stock of Stationery   2,559   3,451 
Cash at Bank and in Hand 12  308,056   5,369 
Short Term Deposits   10,127,002   5,857,283 
    12,520,265   7,530,551 
Creditors - Amounts falling due within one year
Creditors and Accruals 7  6,392,385   5,487,926 
Mortgage 13  793,332   340,000 
    7,185,717   5,827,926 
Net Current Assets   5,334,548   1,702,625 
Long Term Liabilities   
Mortgage 13  11,106,668   11,900,000 
TOTAL NET ASSETS   18,422,424   14,487,130 
Financed by
Income and Expenditure Reserve 11  18,422,424   14,487,130 
    18,422,424   14,487,130
 
Pat o’mahony maureen Windle 
Chairman Board Member
The accounting policies on pages 68 to 69 and the notes on pages 74 to 80 form part of the financial statements.
  note  2009  2008 
   €  €
 Annual Report 2009 73
cash Flow Statement
For the year ended 31 December 2009
Reconciliation of surplus to net cash inflow from operating activities
Surplus for the year  3,935,294 1,812,183
Depreciation Charge  1,502,168 1,606,304
(Increase)/Decrease in Debtors  (418,200) 38,903
(Increase)/Decrease in Stocks  892 1,256
Increase/(Decrease) in Creditors - amounts falling due within one year  904,459 512,091
Deposit Interest   (91,596) (121,894)
Bank Interest and Charges  512,075 528,025
Loss/(Gain) on Disposal of Fixed Assets  1,694 374
Net Cash Inflow from Operating Activities  6,346,786 4,377,242
Cash Flow Statement
Net Cash Inflow from Operating Activities  6,346,786 4,377,242
Return on Investments and Servicing of Finance 8 (420,479) (406,131)
Capital Expenditure 8 (1,013,901) (1,633,906)
Management of Liquid Resources 8 (4,269,719) (2,003,618)
Financing 8 (793,332) (340,000)
Increase/(Decrease) in Cash   (150,645) (6,413)
Reconciliation of net cash flow to movement in net debt
Increase/(Decrease) In Cash  (150,645) (6,413)
Increase/(Decrease) In Short Term Deposits  4,269,719 2,003,618
(Increase)/Decrease In Long Term Finance  793,332 340,000
Change In Net Debt  4,912,406 2,337,205
Net Debt at start of year  (6,377,348) (8,714,553)
Net Debt at end of year 9 (1,464,942) (6,377,348)
The accounting policies on pages 68 to 69 and the notes on pages 74 to 80 form part of the financial statements.
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notes to the Financial Statements 
For the year ended 31 December 2009
1 TANGIBLE ASSETS 
  Fixtures and computer  leasehold  improvements
  Fittings equipment improvements to Premises Premises total
  € € € € € €
 Cost
 Balance as at 1 January 2009  900,338   6,687,322   502,445   3,271,602   20,383,000  31,744,707
 Additions for the year  43,046   940,049   -   30,806   -  1,013,901
 Disposals for the year (25,268) (47,483)  -   -   -  (72,751)
 As at 31 December 2009  918,116   7,579,888   502,445   3,302,408   20,383,000  32,685,857
 Depreciation
 Balance as at 1 January 2009  436,002   5,703,686   199,723   720,791   -  7,060,202
 Charge for the year  164,482   957,200   50,245   330,241   -  1,502,168
 Disposals for the year (23,574) (47,483)  -   -  -  (71,057)
 As at 31 December 2009  576,910   6,613,403   249,968   1,051,032   -  8,491,313
 Net Book value  
 at 31 December 2009  341,206   966,485   252,477   2,251,376   20,383,000  24,194,544
 Net Book value  
 at 1 January 2009  464,336   983,636   302,722   2,550,811   20,383,000  24,684,505
2 INCOME         
   2009  2008 
   € €
 Fee Income
 Clinical Trials   140,211   151,762 
 Human Medicine - National Fees   7,857,555   6,459,620 
 Human Medicine - European Fees   7,857,155   6,837,485 
 Veterinary Medicine - National Fees   1,137,328   1,076,667 
 Veterinary Medicine - European Fees   966,288   915,986 
 Compliance Department   3,292,018   3,087,380 
 Medical Devices   203,101   175,356 
    21,453,656   18,704,256 
 Other Income (Note 3)   4,713,275   5,220,407 
 Total Income   26,166,931   23,924,663 
 
Certain fees, totalling €14,902,621, are required by law to be disposed of in accordance with the directions of the 
Minister for Finance.
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   2009  2008 
   € €
3 OTHER INCOME         
 Dept Of Health and Children Funding   4,602,032   4,993,212 
 IT Income   5,000   5,000 
 Conference Fee Income   15,800   100,675 
 Deposit Interest   91,596   121,894 
 (Loss)/Gain on Disposal of Fixed Assets  (1,694) (374)
 Miscellaneous   541   - 
    4,713,275  5,220,407 
4 SALARIES AND WAGES    
   2009  2008 
   € €
 Salaries and Wages   14,590,623   13,971,860 
 Social Welfare Costs   1,278,581   1,283,827 
    15,869,204   15,255,687 
  
 The average number of staff employed during the year was 270 (2008 – 260).  
 Staff employed at 31 December 2009 can be analysed across the following departments : 
   2009  2008
 Medical Technical   22   18 
 Pharmaceutical Technical   30   32 
 Veterinary Technical   16   12 
 Compliance Technical   19   18 
 Medical Devices Technical   16   17 
 Enforcement Technical   8   9 
 Blood Directive Technical   4   4 
 Controlled Drugs Technical   3   3 
 Tissues and Cells Technical   2   2 
 Chief Executive and Corporate   31   34 
 Operational Staff   105   106 
 Pensioners   13   11 
    269   266
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5 OPERATING COSTS
 Accommodation Costs   1,009,815   1,050,907 
 Travel, Representation and Training   829,890   1,156,870 
 Bank Charges and Interest   512,075   528,025 
 Legal and Professional Fees   979,322   361,706 
 Stationery, Publications and Postage   389,291   422,104 
 Other Operating Costs   1,769,350   2,368,394 
    5,489,743   5,888,006 
6 DEBTORS (ALL DUE WITHIN ONE yEAR)
   2009  2008 
   € €
 Trade Debtors   1,386,893   1,160,040 
 Prepayments   388,605   322,693 
 Other Debtors   307,150   181,715 
    2,082,648   1,664,448
7 CREDITORS (AMOUNTS FALLING DUE WITHIN ONE yEAR) 
   2009  2008 
   € €
 Trade Creditors   997,509   561,913 
 Accruals   4,917,858   4,506,106 
 Revenue   477,018   419,907 
    6,392,385   5,487,926
notes to the Financial Statements 
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   € €
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   2009  2008 
   € €
8 GROSS CASH FLOWS
 Returns on Investment and Servicing of Finance
 Deposit Interest   91,596   121,894 
 Bank Interest and Charges  (512,075) (528,025)
   (420,479) (406,131)
 Capital Expenditure 
 Payments to acquire Tangible Fixed Assets  (1,013,901) (1,634,288)
 Receipts from sales of Tangible Fixed Assets  0  382 
   (1,013,901) (1,633,906)
 Management of Liquid Resources
 (Increase)/Decrease in Short Term Deposits  (4,269,719) (2,003,618)
   (4,269,719) (2,003,618)
 Financing
 Increase/(Decrease) in Long Term Finance  (793,332) (340,000)
   (793,332) (340,000)
9 ANALySIS OF CHANGES IN NET DEBT  
  as at  as at
  01/01/2009 cashflow 31/12/2009
 Cash at Bank and in Hand   5,369  302,687  308,056 
 Short Term Deposits  5,857,283  4,269,719  10,127,002 
 Debt Due Within One Year (340,000) (453,332) (793,332)
 Debt Due After One Year (11,900,000)  793,332  (11,106,668)
  (6,377,348)  4,912,406  (1,464,942)
10 ADMINISTRATION ExPENSES
   2009  2008 
   € €
 Surplus for the year was calculated having charged : 
 Auditor’s Remuneration   17,390   18,500
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11 INCOME AND ExPENDITURE RESERVES
The Income and Expenditure Reserve disclosed in the Balance Sheet  
on page 72 comprises the following :
 Retained Reserves   13,967,287   10,661,471 
 Staff Superannuation Contributions   4,455,137   3,825,659 
    18,422,424   14,487,130
12 CASH AND BANk BALANCES
   2009  2008 
   € €
 Current Account Balances   306,548   3,217 
 Cash on Hand   1,508   2,152 
    308,056   5,369
13 LONG TERM LIABILITIES    
 Mortgage
 On 22 December 2004 the Board purchased its premises at Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, 
Dublin 2. The purchase was financed by way of a mortgage, secured on the premises, of €20,400,000 over 20 years 
from Bank of Ireland Corporate Lending.
The Irish Medicines Board is committed to making the following capital repayments on its mortgage: 
 
   2009  2008 
   € €
 Within one year   793,332   340,000 
 Between one and five years   3,173,328   3,626,660 
 After five years   7,933,340   8,273,340 
    11,900,000   12,240,000
14 INTEREST RATE ExPOSURE    
The IMB have taken all necessary steps to minimise its interest rate exposure by fixing two-thirds  of the borrowings for 
a period of 10 years. The balance of the borrowings are fully offset  by cash reserves. For 2010 it is estimated that the net 
borrowings for which an interest rate exposure may arise is €0.
   2009  2008 
   € €
notes to the Financial Statements 
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    2009  2008 
   €  €
15 FINANCIAL COMMITMENTS
 Operating Leases
 Amounts payable during the next twelve months in respect of leases 
  which expire:
 – within one year   -   - 
 – between one and five years (in respect of Longphort House)   69,031   - 
 – after five years (in respect of Alexandra House)   285,984   285,984 
    355,015   285,984 
On 22 December 2004 the IMB signed a leasehold interest in respect of the 5th floor, Alexandra House, Earlsfort 
Centre, Dublin 2. At 31 December 2009 this lease had 12 years remaining. On 1 June 2010 the IMB signed a leasehold 
interest in respect of the 3rd floor, Longphort House, Earlsfort Centre, Dublin 2. At 1 June 2010 this lease had 4 years 
and 10 months remaining.
16 CAPITAL COMMITMENTS
   2009  2008 
   € €
 Contracted For (Contract Signed)   385,000   430,000 
 Not Contracted For   250,000   230,000 
    635,000   660,000 
17 BOARD REMUNERATION
   2009  2008 
   € €
 Chairman’s Salary   23,478   25,435 
 Board Members’ Travel Expenses   7,798   8,486 
    31,276   33,921 
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18 STAFF REMUNERATION
 Chief Executive’s Remuneration
 Basic Salary   159,544   158,965 
 Performance Related Payment   22,255   22,500 
    181,799   181,465
The Chief Executive’s pension entitlements do not extend beyond the standard entitlements in the model public sector 
defined benefit superannuation scheme.
19 RELATED PARTy TRANSACTIONS
There have been no transactions with related parties which require disclosure under Financial Reporting Standard 8.
20 PROMPT PAyMENT OF ACCOUNTS     
The Irish Medicines Board (IMB) confirms that it is complying with EU law in relation to prompt payments of account.
21 ExCHANGE RATES     
The exchange rates used in preparing these financial statements were as follows :
2009 €1 = STG £0.8881
2008 €1 = STG £0.9525
22 PROVISIONS     
The Board has been notified of a number of legal proceedings or potential proceedings. The information usually 
required by FRS 12 Provisions, contingent liabilities and contingent assets is not disclosed as the Board believes that to 
do so would be prejudicial to the outcome.
In 2009 the Board was the unsuccessful defendant in a Supreme Court appeal, the issue of costs and damages have 
been referred back to the High Court. The Board is satisfied that they have made adequate provision against any 
award. 
23 GOING CONCERN
The Board has a reasonable expectation, at the time of approving the financial statements, that the IMB has adequate 
resources to continue its operations. For this reason, the Board continues to adopt the going concern basis in preparing 
the financial statements.
24 APPROVAL OF FINANCIAL STATEMENTS
The financial statements were approved by the Board on 24 June 2010. 
    2009  2008 
   € €
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Management Committee
Mr. Patrick O’Mahony – Chief Executive
Dr. J. Gabriel Beechinor – Director of Veterinary Medicines
Dr. Joan Gilvarry – Director of Human Products Monitoring 
Ms. Frances Lynch – Director of Human Resources
Mr. John Lynch – Director of Compliance
Ms. Suzanne McDonald – Director of Information 
Technology and Change Management
Dr. Mike Morris – Senior Scientific Advisor
Ms. Ann O’Connor – Director of Human Products 
Authorisation and Registration 
Ms. Rita Purcell – Director of Finance and Corporate Affairs
Board
Mr Pat O’Mahony – Chairman
Prof. Brendan Buckley
Mr. Pat Brangan
Mr. Wilfrid J. Higgins
Ms. Ingrid Hook
Mr. Brendan McLaughlin
Ms. Cicely Roche
Ms. Maureen Windle
Audit Committee
Ms. Maureen Windle – Chairman
Mr. Pat Brangan
Advisory Committee for Human Medicines
Prof. Brendan Buckley – Chairman
Dr. Paul Browne
Ms. Eugenie Canavan
Dr. Kevin Connolly
Dr. Des Corrigan
Prof. Mary Horgan
Prof. John Kelly
Dr. David Kerins
Ms. Marita Kinsella
Mr. Tom McGuinn
Dr. Bernard Silke 
Dr. Patrick A. Sullivan
Advisory Committee for Veterinary Medicines 
Mr. Pat Brangan – Chairman
Mr. Tom Barragry
Dr. Ruaidhri Breathnach
Ms. Eugenie Canavan
Mr. Michael Clancy
Prof. Ann Cullinane
Mr. Tom McGuinn
Mr. Raymond Muldoon
Dr. Hamish Rodger
Dr. Donal Sammin
Advisory Committee for Medical Devices
Mr. Wilfrid J. Higgins – Chairman
Dr. Geoff Chadwick
Ms. Maureen D’Arcy
Ms. Aideen Drury-Byrne
Dr. John Keogh
Prof. Robert McConnell
Dr. Brendan McCormack
Dr. Tim McGloughlin
Dr. John O’Mullane
Ms. Maebh Smith
Prof. Wil van der Putten
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Experts Sub-Committee of the Advisory Committee 
for Human Medicines
Prof. Mary Horgan – Chairman
Prof. Brendan Buckley
Dr. Colin Buckley
Dr. Owen Carey
Dr. Kevin Connolly
Dr. Noreen Dowd
Dr. Stephen Eustace
Prof. Michael Fitzgerald
Dr. Stephen Flint
Dr. Tim Fulcher
Dr. Joseph Galvin
Dr. Patrick Gavin
Dr. Kevin Kelleher
Dr. Mary Keogan
Prof. David Kerins
Dr. Lorraine Kyne
Dr. Mark Ledwidge
Dr. John McCaffrey
Dr. Patricia McCormack
Prof. Aidan McCormick
Dr. Frank Murray
Dr. Yvonne O’Meara
Mr. Ashley Poynton
Dr. Brion Sweeney
Dr. Jogin Thakore
Dr. Douglas Veale
Clinical Trial Sub-Committee of Advisory Committee 
for Human Medicines
Dr. Patrick A. Sullivan – Chairman
Prof. David Bouchier-Hayes
Dr. Paul Browne
Dr. Brian Cantwell
Dr. Peter A. Daly
Prof. Ted Dinan
Prof. Sidney Lowry
Dr. Tom Pierce
Dr. John Taaffe
Advisory Sub-Committee for Herbal Medicines
Dr. Des Corrigan – Chairman
Dr. Fiona Barry
Dr. Kevin Connolly
Ms. Nicola Darrell
Ms. Ingrid Hook
Ms. Claudine Hughes
Ms. Helen McCormack
Dr. Hugh McGlynn
Dr. Diarmaid O’Connell
Dr. Donal O’Mathuna
Dr. Camillus Power
Dr. Helen Sheridan
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appendix ii : 
glossary
acmd Advisory Committee for Medical 
Devices 
aoti Association of Occupational Therapists 
of Ireland
aSr Annual Safety Report 
atmPs Advanced Therapy Medicinal Products 
beai Biomedical/Clinical Engineering 
Association of Ireland 
bPWP Blood Products Working Party
bWP Biological Working Party 
cat Committee for Advanced Therapies 
cd Controlled drugs
chmP Committee for Human Medicinal 
Products
cmd(h) Co-ordination Group for Mutual 
Recognition and Decentralised 
Procedures - Human
cmd(v) Co-ordination Group for Mutual 
Recognition and Decentralised 
Procedure - Veterinary
coen Compliance and Enforcement Working 
Group
comP Committee for Orphan Medicinal 
Products 
ctFg Clinical Trials Facilitation Group 
ctS Common Technical Specifications 
cVmP Committee for Veterinary Medicinal 
Products 
dcP Decentralised Procedure 
dhPc Direct Healthcare Professional 
Communications
dia Drug Information Association
dmF Drug Master File
dohc Department of Health and Children 
dPr Dual Pack Registration
dSn Drug Safety Newsletter
ectd Electronic Common Technical Dossier
eea European Economic Area 
ehn European Haemovigilance Network
ema European Medicines Agency
erci Electro-Technical Council of Ireland 
eu European union 
euStite Eu Project for Standards and 
Training for the Inspections of Tissue 
Establishments 
eWP Efficacy Working Party 
Fda Food and Drug Administration 
FScs Free Sale Certificates 
gcP Good clinical practice 
gdP Good distribution practice 
gmP Good Manufacturing Procedure 
gtWP Gene Therapy Working Party
h1n1 Pandemic A Influenza
hmPc Committee on Herbal Medicinal 
Products 
hSe Health Service Executive 
icSrs Individual Case Safety Reports
ieQaS Irish External Quality Assessment 
Scheme
imb Irish Medicines Board
imda Irish Medical Devices Association 
iVd In-vitro diagnostic 
lono letter of No Objection
mahs Marketing authorisation holders
mdeg Medical Devices Expert Group
meddeV European Commission DG Enterprise 
and Industry – Medical Devices 
Guidance Document 
mia Manufacturing and Importation 
Authorisations 
mimS Monthly Index of Medical Specialities 
mr Mutual recognition 
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nbog Notified Body Operations Group
ncar National Competent Authority reports
nho National Haemovigilance Office
nirS Near Infrared Spectroscopy 
non ectd Non Electronic Common Technical 
Dossier
nSai National Standards Authority of Ireland
omcl Official Medicines Control laboratories 
Pa Product Authorisation 
Pdco Paediatrics Committee
PhVWP Pharmacovigilance Working Party
Poct Point of Care Testing 
PPa Parallel Import Applications
Preg Pharmacovigilance Rapid Response 
Group
PSur Periodic Safety update Report 
QmS Quality Management System
rio Regulatory Information Online 
Sae Suspected Adverse Event
Sar Suspected Adverse Reaction 
SaWP Scientific Advisory Working Party 
SohoV&S Substances of Human Origin Vigilance 
and Surveillance
SPcs Summary of Product Characteristics 
umc uppsala Monitoring Centre
vcJd Variant Creutzfeldt – Jakob Disease
VPa Veterinary Product Authorisation 
Who World Health Organisation 
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